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CHAIN-MODIFIED PYRIDINO-N
SUBSTITUTED NICOTINE COMPOUNDS
FOR USE IN THE TREATMENT OF CNS
PATHOLOGIES

abundant in the CNS, are the receptors labeled by [3Hmeth

yllycaconitine (MLA), Which has high af?nity for the (X7
homomeric nicotinic receptor subtype. Additionally, nico
tinic receptor subtypes can be studied using functional
assays such as NIC-evoked [3H]dopamine (DA) release

RELATED APPLICATIONS

from rat striatal slices. Nicotinic receptors are located on the

cell body and terminals of the nigrostiatal pathWay. NIC

This application claims priority from US. Provisional
Patent Application Ser. No. 60/342,120, ?led Dec. 26, 2001.

facilitates DA release from striatal nerve terminals. Studies

strongly suggest that the [3H]DA release assay is useful to

probe (x3 [32* nicotinic receptor subtypes.

FIELD OF THE INVENTION

Structural and functional diversity of CNS nicotinic
receptors has stimulated a great deal of interest in develop

This invention relates to chain-modi?ed analogs of N-n

octylnicotinium iodide (NONI) and N-n-decylnicotinium

ing novel, subtype-selective agonists. Some of these ago

iodide (NDNI) that have selective (x3 [32* and (>t4[32 nicotinic
receptor antagonist properties respectively, and to a method

nists are currently being evaluated in clinical trials for

of using such compounds to treat central nervous system

cognitive enhancement and neuroprotective effects poten

pathologies. The present invention also relates to pharma
ceutical compositions containing these compounds, as Well

tially bene?cial for disease states such as AlZheimer’s and

as various uses thereof.

20

Parkinson’s Disease. Surprisingly, little attention has been
focused on developing subtype-selective antagonists for
neuronal nicotinic receptors. Potential uses of nicotinic

BACKGROUND OF THE INVENTION

Formula (I) beloW shoWs the structure of S-(—)-nicotine
(NIC), Which activates neuronal nicotinic receptors evoking
release of dopamine (DA) from presynaptic terminals in the

receptor anatagonists are for the treatment of psychostimu

lant abuse, smoking cessation, and schizophrenia.
25

central nervous system (CNS). NIC is a legal substance of
dependence that produces many of its effects on the CNS,

nomenclature is given in parentheses.

some of Which may be considered to be bene?cial e.g., mood

elevation, arousal and learning and memory enhancement.
NIC produces its effect by binding to a family of ligand

A class of pyridino N-substituted nicotine analogs having
formula (IV) beloW are knoWn antagonists that have a?inity
in the [3H]NIC binding assay and demonstrate the ability to
inhibit NIC-evoked [3 H] DA release. The abbreviated

30

gated ion channels, stimulation by acetylcholine (ACh) or
NIC causes the ion channel to open, and cations to ?ux With

a resulting rapid (in millisec) depolariZation of the target
cell.
Over the last 12 years, there has been a substantial
increase in studies on brain nicotinic receptors. Adult

peripheral nicotinic muscle receptors are composed of four
subunit domains: 2a, [3, y and 6. Traditional peripheral
nicotinic receptor antagonists are shoWn in formula (II) and

35

CH3

/
N

40

(III), i.e. decylmethonium (DEC) (muscle), hexamethonium
(HEX) (ganglionic), and d-tubocurarine (d-Tc) (muscle).
These compounds have also shoWn the ability to Weakly
inhibit neuronal nicotinic receptors.
Neuronal nicotinic receptors are composed of only tWo

\ \\\\‘

I

iHg
iHg
H3C BNVWVNQ
[
"
[ CH3
CH3

H

CH3

2 C16
45

subunits, 0t and [3 and are believed to assemble With the

2.) n I 4 (HEX)
b) n I 8 (DEC)

general stoichiometry of 2a and 3[3. Nine subtypes of the ot
subunit (a2 to (x10) and three subtypes of the [3 unit ([32 to
[34) are found in CNS. The most common nicotinic receptor

species in the brain is composed of tWo (X4 and three [32

50

III

subunits, i.e., (X462. These subunits display different, but
overlapping, patterns of expression in the brain.
For the most part, the actual subunit compositions and
stoichiometries of nicotinic receptors in the brain remain to

be elucidated. Thus, neuronal nicotinic receptor subtype
diversity originates from differences in the amino acid

55

sequence at the subunit level and from the multiple combi
nations of assemblies of subunits, Which can form functional

receptor proteins.
In spite of the extensive diversity in neuronal nicotinic
receptor messenger RNA expression, only a limited number
of tools are available to study the pharmacology of native
receptors. Radioligands are used in many such studies.

60

[3H]NIC appears to label the same sites in the brain as

[3H]ACh. It has been estimated that over 90% of [3H]NIC
binding in the brain is due to association With the hetero
meric receptor that is composed of (X4 and [32 subunits. Also

65

oCH3
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3

preferred embodiments of the invention are shoWn and

described, simply by Way of illustration of the best mode of
carrying out the invention. As is readily recogniZed the
invention is capable of modi?cations Within the skill of the
relevant art Without departing from the spirit and scope of

-continued

the invention.
DETAILED DESCRIPTION OF THE
INVENTION
a.)
b)
c)
d)
e)

The present invention provides novel compounds, includ
ing resolved enantiomers and diastereoisomers, having a
formula selected from formula (V) or formula (VI) beloW:

R I (CH2)7CH3 (NONI)
R I (cnmcn3 (NNNI)
R I (cnmcn3 (NDNI)
R I (CH2)10CH3 (NUNI)
R I (CH2)11CH3 (NDDNI)

(V)
These compounds are useful in the treatment of nicotine
abuse, smoking cessation therapy, as an antidote for nicotine
intoxication, treatment of cognitive disorders such as AlZhe
imer’s disease and for the treatment of Parkinson’s disease.
These compounds and their method of use Were the subject
of US. Pat. No. 5,691,365, issued Nov. 25, 1997. The

20

content of this patent is incorporated herein by reference.
The invention disclosed herein is directed to a series of

ef?cacious and subtype-selective nicotinic antagonists at
nicotinic receptors in the CNS. These compounds comprise

25

(VI)

alkenyl alkynyl, branched and cyclic pyridine-N substituted
NIC analogs.
SUMMARY OF THE INVENTION

30

The present invention provides for chain-modi?ed ana

logs of N-n-octylnicotinium iodide (NONI) and N-n-de
cylnicotinium iodide (NDNI) having potent and selective
antagonistic activity at certain neuronal nicotinic receptor
subtypes. These compounds competitively inhibit CNS
nicotinic receptor agonists and act at (x3 [32* or (x462 neuronal
nicotinic receptor subtypes in the CNS.
A preferred embodiment of the invention provides for a

method of antagoniZing the nicotinic receptor comprising

40

administering of a pharmaceutically e?‘ective amount of a

substituted alkenylene group having 1I3 carbon atoms,

compound of the invention.

C(O), O, C(S), S, S(O) and S(O)2 containing alkylene

Still another embodiment the invention provides a method

for the treatment of psychostimulant abuse (including nico

Wherein
Q is selected from the group consisting of a straight chain
or branched alkylene group having 1% carbon atoms, a

45

moiety, provided that any heteroatom contained in Q is

tine abuse, amphetamine abuse, methamphetamine abuse,

separated from N by at least one carbon atom;

and cocaine abuse), alcohol abuse, as a smoking cessation
therapy, as an antidote for nicotine intoxication comprising
administering of a pharmaceutically e?‘ective amount of a
compound according to the invention, as a therapeutic agent
for the treatment of pathologies of the GI tract, including
irritable boWel syndrome, colitis and related disorders.
This invention further provides a method of treatment of
CNS disorders associated With the alteration of normal

50

R1 is selected from the group consisting of hydrogen,
loWer straight chain or branched alkyl, cycloalkyl having
1I6 carbon atoms, substituted cycloalkyl having 1I6 carbon
atoms, aryl, aralkyl, or heterocyclic group;
R2, Z1 and Z4 are each independently selected from the
group consisting of hydrogen, loWer alkyl, loWer branched
alkyl, loWer alkenyl, and loWer branched alkenyl;

neurotransmitter release in the brain, including conditions

55

such as AlZheimer’s disease as Well as other types of

dementia, Parkinson’s disease, cognitive dysfunction (in
cluding disorders of attention, focus and concentration),
attention de?cit syndrome, a?fective disorders, mood and
emotional disorders such as depression, panic anxiety and

60

psychosis, Tourette’s syndrome, schizophrenia, eating dis
orders and the control of pain comprising administering of
a pharmaceutically e?‘ective amount of a compound accord

ing to the invention.
The above and other objects of the invention Will become
readily apparent to those of skill in the relevant art from the

folloWing detailed description and ?gures, Wherein only the

65

A and B are selected from nitrogen or carbon With the
proviso that When A or B is nitrogen, R3 or R4 cannot be

present;
R3, R4, Z2 and Z3 are each independently selected from
the group consisting of hydrogen; alkyl; substituted alkyl;
cycloalkyl; substituted cycloalkyl; substituted alkenyl; sub
stituted alkenyl; alkynyl; substituted alkynyl; aryl; substi
tuted aryl; alkylaryl; substituted alkylaryl; arylalkyl; substi
tuted arylalkyl; arylalkenyl; substituted arylalkenyl;
arylalkynyl; substituted arylalkynyl; heterocyclic; substi
tuted heterocyclic; tri?uoromethyl; halogen; cyano; nitro;

S(O)Yl, S(O)2Yl, S(O)2OY' or S(O)2NHY1, Wherein each
Y is independently hydrogen, loWer alkyl, alkenyl, alkynyl
or aryl, With the proviso that When R3, R4 or R5 is S(O)Y1,

US 7,091,357 B2
5

6

Y1 is not hydrogen, and With the further proviso that When
Y1 is alkenyl or alkynyl, the site of unsaturation is not
conjugated With a heteroatom; C(O)Y2, Wherein Y2 is

hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted
alkynyl, aryl, substituted aryl, alkylaryl, substituted alky
laryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het

selected from hydrogen, alkyl, substituted alkyl, alkoxy,
alkylamino, alkenyl, substituted alkenyl, alkynyl, substi
tuted alkynyl, aryl, substituted aryl, aryloxy, arylamino,
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub

erocyclic, substituted heterocyclic or tri?uoromethyl, With
the proviso that the SY4 functionality is not conjugated With
an alkenyl or alkynyl functionality; and With the further
proviso that When A and B are carbon, R5 is not N-alkyl or

stituted arylalkynyl, heterocyclic, substituted heterocyclic or
tri?uoromethyl, With the proviso that the carbonyl function

branched alkyl With 2*l 9 carbon atoms, cycloalkyl, aralkyl,

ality is not conjugated With an alkenyl or alkynyl function

N-alkenyl or alkenyl With 2*l9 carbon atoms, or N-alkynyl
or branched alkynyl With 2 to 19 carbon atoms;

ality; OY3 or N(Y3)2 Wherein each Y3 is independently

selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
heterocyclic, substituted heterocyclic, acyl, tri?uoromethyl,
alkylsulfonyl or arylsulfonyl, With the proviso that OY3 or
N(Ys)2 functionality is not conjugated With an alkenyl or

R6 is hydrogen;
X is selected from the group consisting of Cl, Br, I, HSO4,

1/2802, CH3SO3, p-TsO and CF3SO3; and
Y is selected from the group consisting of 2C1, 2Br, 2l,

2HSO4, S02, 2CH3SO3, 2p-TsO and 2CF3SO3.
When R3 and R4 together form a three to eight membered
saturated or unsaturated ring or either 1 and Z2 or 1 and Z3
20

alkynyl functionality; SY4 Wherein Y4 is selected from

hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted
alkynyl, aryl, substituted aryl, alkylaryl, substituted alky
laryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het

saturated or unsaturated ring selected from the group con

sisting of benZene, pyridine, pyran, indene, isoindene, ben
25

erocyclic, substituted heterocyclic or tri?uoromethyl, With
the proviso that the SY4 functionality is not conjugated With
an alkenyl or alkynyl functionality; or R3 and R4 together
form a three to eight membered saturated or unsaturated

30

may optionally and independently be replaced by a nitrogen,
oxygen or sulfur atom, and Wherein said rings may option
ally be substituted With one or more substituents that are
35

pyrrole,

dec ahydro -quinoline,

and

1 -methyl -

It is preferred that Q is either CH2, CH2CH2, CH=CHi,
C(CH3)=CH, CH=(C(CH3), or C(CH3)=C(CH3); A and
40

B are each carbon; R1 is a CFC1O alkyl or more preferably
a CFC6 alkyl alkyl or even more preferably a CFC4 alkyl

such as methyl, ethyl, isopropyl or isobutyl; R2 is hydrogen;
R3 and R4 are individually selected from the group consist

heterocyclic; substituted heterocyclic; S(O)Yl', S(O)2Yl,
S(O)2OYl or S(O)2NHYl, Wherein each Y1 is independently
hydrogen, loWer alkyl, alkenyl, alkynyl or aryl, With the
proviso that When R3, R4 or R5 is S(O)Y1, Y1 is not

romen-3-one, quinoline, isoquinoline, cinnoline, quinaZo
line, naphthyridine, pyrido[3,4-b]-pyridine, pyridol[3,2-b]
pyridine, pyrido[4,3-b]-pyridine, benZoxaZine, anthracene,
phenanthrene, phenalene, ?uorene, caraZole, xanthene, acri
dine, octahydro-[l]pyridine, l-methyl octahydro-[l]pyri
dine, octahydro-indole, l-methyl octahydro-indole, octahy
dro-cyclopenta[b]pyrrole, l-methyl-octahydrocyclopenta[b]

decahydroquinoline.

and Z4 together form a spiro ring structure;
R5 is selected from the group consisting of alkyl; substi

tuted alkyl; cycloalkyl; substituted cycloalkyl; alkenyl; sub
stituted alkenyl; alkynyl; substituted alkynyl; aryl; substi
tuted aryl; arylalkyl; substituted arylalkyl; arylalkenyl;
substituted arylalkenyl; arylalkynyl; substituted arylalkynyl;

Zofuran, isobenZofuran, benZo[b]thiophene, benZo[c]
thiophene, indole, indolenine, isoindole, cyclopental[b]
pyridine, pyrano[3,4-b]pyrrole, indaZole, indoxaZine,
benZosaZole, anthranil, naphthalene, tetralin, decalin,
chromene, coumarin, chroman-4-one, isocoumarin, isoch

ring, Wherein from one to three carbon atoms of said ring

de?ned as Z3 and Z4; or either Z1 and Z2 or Z1 and Z3
together form a fused ring structure; or either Z2 and Z4 Z3

together form a fused ring structure, the fused ring or

ing of hydrogen, halogen, alkyl or alkanoyl; R5 is a branched
45

or non-branched C(Cl9 alkyl, cycloalkyl, alkenyl, alkynyl,
aryl, arylalkyl arylalkenyl, arylalknyl; Z1, Z2, Z3 and Z4 are
each hydrogen, or Z3 and Z4 are hydrogen, Z1 and Z2 and

hydrogen, and further With the proviso that When Y1 is
alkenyl or alkynyl, the site of unsaturation is not conjugated
With a heteroatom; C(O)Y2, Wherein Y2 is selected from

their associated carbon atoms combine to form a ?ve or six

hydrogen, alkyl, substituted alkyl, alkoxy, alkylamino, alk
enyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl,
substituted aryl, aryloxy, arylamino, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, sub
stituted arylalkenyl, arylalkynyl, substituted arylalkynyl,

50

heterocyclic, substituted heterocyclic or tri?uoromethyl,
With the proviso that the carbonyl functionality is not

55

membered fused ring structure, or Z2 and Z4 are hydrogen,
Z1 and Z3 and their associated carbon atoms combine to
form a ?ve or six membered fused ring structure, or Z1 and

Z3 are hydrogen, Z2 and Z4 and their associated carbon
atoms combine to form a ?ve or six membered spiro ring

structure, or Z1 and Z2 are hydrogen, Z3 and Z4 and their
associated carbon atoms combine to form a ?ve or six

membered spiro ring structure; and X is iodine or bromine.

As employed herein, the meaning of the aforementioned

conjugated With an alkenyl or alkynyl functionality; OY3 or

N(Y3)2 Wherein each Y3 is independently selected from

terms are de?ned as folloWs:

hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted
alkynyl, aryl, substituted aryl, alkylaryl, substituted alky
laryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het
erocyclic, substituted heterocyclic, acyl, tri?uoromethyl,

“loWer alkyl” refers to straight or branched chain alkyl
radicals having in the range of about 1 up to 4 carbon atoms;
“alkyl” refers to straight or branched chain alkyl radicals
having in the range of about 1 up to 19 carbon atoms and

“substituted alkyl” refers to alkyl radicals further bearing
one or more substituents such as hydroxy, alkoxy (of a loWer

or N(Y3)2 functionality is not conjugated With an alkenyl or

alkyl group), mercapto (of a loWer alkyl group), aryl,
heterocyclic, halogen, tri?uoromethyl, cyano, nitro, amino,

alkynyl functionality; SY4 Wherein Y4 is selected from

carboxyl, carbamate, sulfonyl, sulfonamide, and the like.

alkylsulfonyl or arylsulfonyl, With the proviso that the OY3

65

US 7,091,357 B2
8

7
“cycloalkyl” refers to cyclic ring-containing moieties

A pharmaceutical composition containing a compound of

containing in the range of about 3 up to 8 carbon atoms and

the invention is also contemplated, Which may include a
conventional additive, such as a stabiliZer, bulfer, salt,
preservative, ?ller, ?avor enhancer and the like, as knoWn to

“substituted cycloalkyl” refers to cycloalkyl moieties further
bearing one or more substituent as set forth above;

“alkenyl” refers to straight or branched chain hydrocarbyl

those skilled in the art. Representative bulfers include phos
phates, carbonates, citrates and the like. Exemplary preser
vatives include EDTA, EGTA, BHA, BHT and the like. A
composition of the invention may be administered by inha

groups having at least one carbon-carbon double bond, and
having in the range of about 2 up to 19 carbon atoms and

“substituted alkenyl” refers to alkenyl groups further bearing
one or more substituents as set forth above;

lation, i.e., intranasally as an aerosol or nasal formulation;
topically, i.e., in the form of an ointment, cream or lotion;

“alkynyl” refers to straight or branched chain hydrocarbyl
moieties having at least one carbon-carbon triple bond, and

orally, i.e., in solid or liquid form (tablet, gel cap, time
release capsule, poWder, solution, or suspension in aqueous

having in the range of about 2 up to 19 carbon atoms and

“substituted alkynyl” refers to alkynyl moieties further bear

or non aqueous liquid; intravenously as an in?sion or

ing one or more substituents as set forth above;

injection, i.e., as a solution, suspension or emulsion in a

“aryl” refers to aromatic groups having in the range of 6
up to 24 carbon atoms and “substituted aryl” refers to aryl

pharmaceutically acceptable carrier, transdermally, e.g., via
a transdermal patch; rectally as a suppository and the like.

groups further bearing one or more substituents as set forth

The present invention includes all possible diastereomers

above;
“alkylaryl” refers to alkyl-substituted aryl groups and
“substituted alkylaryl” refers to alkylaryl groups further
bearing one or more substituents as set forth above;

and all enantiomeric forms as Well as racemic mixtures. The

compounds can be separated into substantially optically pure
20

compounds. The compounds of the invention are nicotinic

receptor agents. They inhibit [3H]NIC binding and [3 H]

“arylalkyl” refers to aryl-substituted alkyl groups and
“substituted arylalkyl” refers to arylalkyl groups further

MLA binding and NlC-evoked [3H]DA release.
Examples of compounds falling Within the scope of the

bearing one or more substituents as set forth above;

“arylalkenyl” refers to aryl-substituted alkenyl groups and
“substituted arylalkenyl” refers to arylalkenyl groups further

present invention precede the appended claims. If one spe

bearing one or more substituents as set forth above; “ary

may readily be made from the appropriate chiral precursor

lalkynyl” refers to aryl-substituted alkynyl groups and “sub
stituted arylalkynyl” refers to arylalkynyl groups further

or can be resolved from a racemic mixture.

ci?c enantiomer is shoWn or described, the other enantiomer

bearing one or more substituents as set forth above;

“aroyl” refers to aryl-substituted species such as benZoyl
and “substituted aroyl” refers to aroyl moieties further

30

VI

bearing one or more substituents as set forth above;

“heterocyclic” refers to cyclic moieties containing one or
more heteroatoms as part of the ring structure, and having in
the range of 3 up to 24 carbon atoms and “substituted

35

heterocyclic”refers to heterocyclic moieties further bearing
one or more substituents as set forth above; “acyl” refers to

alkyl-carbonyl species;
“halogen” refers to ?uoride, chloride, bromide or iodide
groups.

40

Examples of pharmaceutically acceptable salts include
inorganic and organic acid addition salts such as hydrochlo

ride, hydrobromide, nitrate, sulfate, phosphate, acetate,
methanesulfonate, p-toluenesulfonate, benZenesulfonate,
salicylate, propionate, ascorbate, aspartate, fumarate, galac
tarate, maleate, citrate, glutamate, glycolate, lactate, malate,
maleate, tarrate, oxalate, succinate, or similar pharmaceuti
cally-acceptable inorganic or organic acid addition salts, and
include the pharmaceutically acceptable salts listed in the
Journal ofPharmaceuZical Science, 66, 2. (1977) Which are
hereby incorporated by reference. The above salt forms may

mIZ
mI3

45

50

be in some cases hydrates or solvates With alcohols and other

solvents.
When used in reference to compounds of the invention,
“an effective amount” refers to doses of compound suf?cient

to provide circulating concentrations high enough to impart

55

a bene?cial effect on the recipient thereof for alleviating a
disease or pathological symptom of a CNS pathology. The

n I 6 NONB-7e
n I 8 NDNB-9e

amount to be administered depends to some extent on the

lipophilicity of the speci?c compound selected, since it is
expected that this property of the compound Will cause it to

n I 9 NUNB-lOe

60

partition into fat deposits of the subject. The precise amount
to be administered can be determined by the skilled practi
tioner in vieW of desired dosages, side effects and medical

history of the patient and the like. It is anticipated that the
compound Will be administered in the amount ranging
1><10 to about 100 mg/kg/day, With amounts in the range of

about 1><10_2 up to 1 mg/kg/day being preferred.

n I 1 NCyNB-4

65

n I 2 NCyNB-S
n I 3 NCyNB-6

US 7,091,357 B2
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(S)-1-Dec-9-enyl-3 -(1-methyl-pyrrolidin-2-yl)-pyridinium
bromide (NDNB-9e);

-continued

(S)-3 -(1-Methyl-pynolidin-2-yl)-1-undec-10-enyl-pyri
dinium bromide (NUNB- 1 0e);

+

\

N

\

\
+/

cH3

N

N

5

/\
+/

H

(S)-1-(6-Cyclobutyl-hexyl)3 -(1-methyl-pyrrolidin-2-yl)-py
ridinium bromide hydrobromide salt (NCyNB -4);

(S)-1-(6-Cyclopentyl-hexyl)-3 -(1-methyl-pyrrolidin-2-yl)

cH3

pyridinium bromide hydrobromide salt (NCyNB-5);

N

(S)-1-(6-Cyclohexyl-hexyl)-3 -(1-methyl-pyrrolidin-2-yl)
_

Bf

10

2Br

pyridmium bromide hydrobromide salt (NCyNB-6);

(S)-3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-3 -ynyl-pyridinium
bromide (NONB -3y);

(S)-1-Dec-3 -ynyl-3 -(1-methyl-pyrrolidin-2-yl)pyridinium
bromide (NDNB -3y);
15

< >.

(S)-1-(7-Methyl-oct-6-enyl)-3 -(1-methyl-pyrrolidin-2-yl)
pyridinium bromide hydrobrormide (NONB-6e7M);

\

(S)-1-(7-Methyl-octyl)-3 -(1-methyl-pyrrolidin-2-yl)-pyri
dinium bromide hydrobromide salt (NONB-7M);

n I 2 NONE-3y
n I 4 NDNB-3y

20

NONB—6e7M

(S)-1-[2-(2-Ethoxy-ethoxy)-ethyl]-3-(1-methyl-pyrrolidin
2-yl)-pyridinium bromide (NONB -3060);

(S)-1-(9-Acetoxy-nonyl)-3 -(1-methyl-pyrrolidin-2-yl)-pyri
dinium bromide (NANNB);

(S)-1-(11-Acetoxy-undecyl)-3 -(1-methyl-pyrrolidin-2-yl)

+

\

N
/ \

+/

H

cH3

N

\

N

25
+/

cH3

pyridinium bromide (NAUNB);

(S)-1-(12-Acetoxy-dodecyl)-3 -(1-methyl-pyrrolidin-2-yl)
pyridinium bromide (NADDNB);

N

These compounds can be prepared from corresponding
free bases by reaction With an appropriate alkyl iodide using
2Br'

Br‘

techniques knoWn to those skilled in the art of organic
30

O

synthesis.
The invention Will noW be described in greater detail by

reference to the folloWing non-limiting examples.
EXAMPLE 1

O>
NONB-7M

NONB-306O

35
40

(S)-trans-3-(1-Methyl-pyrrolidin-2-yl)-1-oct-3-enyl
pyridinium bromide hydrobromide salt (NONB-3t)
1a. trans-Oct-3-en-1-ol

A solution of oct-3-yn-1-ol (2.52 g, 20.0 mmol), t-BuOH
(5 g), THF (10 mL) and liquid NH3 Was cooled to —360 C.
\

I

cH3

+/
N

>>n

0

>

Pieces of Lithium (0.34 g, 50 mmol) Were introduced With

N

vigorous stirmg and maintaining the temperature. After 2 h,
45

50 next step Without further puri?cation: 1H NMR (300 MHZ,

H3C

CDCl3) 6 5.54 (1H, m), 5.36 (1H, m), 3.66 (2H, t, JI6.3 HZ),
2.25 (2H, m), 2.02 (2H, m), 1.74 (1H, br s), 1.31 (4H, m),
0.88 (3H, t, JI7.2 HZ); 13C NMR (75 MHZ, CDCl3) 6
134.27, 125.78, 62.22, 36.22, 32.59, 31.86, 22.47, 14.20.

n I 9 NANNB
n I ll NAUNB
n I 12 NADDNB

55

(S) -trans -3 -(1-Methyl-pyrolidin-2-yl)-1-oct-3 -enyl-pyridu
ium bromide hydrobromide salt (NONB -3t);
(S) -trans-1 -Dec -4-enyl-3 ( 1 -methyl-pyrrolidin-2 -yl)-pyri
dinium bromide (NDNB-4t);

(S) -cis-3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-3 -enyl-pyri
dinium bromide hydrobromide salt (N ONE -3 c);
(S) -cis-1 -Dec -4 -enyl-3 -(1-methyl-pyrrolidin-2-yl)-pyri
dinium bromide hydrobromide salt (N DNB -4c);

(S) -3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-7-enyl -pyridinium
bromide (NONB-7e);

solution Was added and the reaction mixture Was extracted

With hexane. The combined organic layers Were Washed
With 1 M HCl, aqueous NaHCO3 and brine successively and
dried. Evaporation of the solvent gave trans-oct-3-en-1-ol
(2.44 g, 95%) as a pale yelloW oil, Which Was used in the

Bl‘

O

NH3 Was alloWed to evaporate overnight. Saturated NH4Cl

1b. trans-1-Bromo-oct-3-ene
To a solution of trans-oct-3-en-1-ol (1.28 g, 10.0 mmol)

in DMF (25 mL) Was added triphenylphosphine (2.92 g,
11.1 mmol). The solution Was cooled to 00 C. and NBS (1.92
g, 10.8 mmol) Was added in portions. After stirring for 30

60 min at room temperature, the reaction Was quenched With
methanol (1 mL). The solution Was diluted With ether (100

mL), Washed With Water, saturated aqueous NaHCO3 and
brine successively. The organic layer Was dried and concen
trated. The residue Was puri?ed by ?ash chromatography on
silica gel, eluting With hexane to afford trans-1-bromo-oct
3-ene (1.40 g, 73%) as a colorless oil: 1H NMR (300 MHZ,

CDCl3) 6 5.54 (1H, m), 5.39 (1H, m), 3.37 (2H, t, JI7.2 HZ),

US 7,091,357 B2
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2.54 (2H, m), 2.02 (2H, m) 1.34 (4H, m), 0.89 (3H, 1, 1:72
HZ); 13C NMR (75 MHZ, CDC13) 0 134.09, 126.45, 36.34,
33.21, 32.48, 31.73, 22.45, 14.24.
1c. (S)-trans-3-(1-Methyl-pyrrolidin-2-yl)-1-oct-3enyl-pyri
dinium bromide hydrobromide salt (NONB-3t)

tion of the solvent folloWed by titration With ether afforded

0.82 g (74%) of (S)-trans-1-dec-4-enyl-3-(1-methyl-pyrro
lidin -2-yl)-1-pyridinium bromide (NDNB-4t) as a broWn

oil. 1H NMR (300 MHZ, CDCl3) 6 9.71 (1H, d, J:5.7 HZ),
9.07 (1H, s), 8.40 (1H, d, 1:81 HZ), 8.08 (1H, dd, 1:81, 6.0
HZ), 5.42 (2H, m), 5.00 (2H, t, 1:69 HZ), 3.54 (1H, t, J:8.4
HZ), 3.25 (1H, m), 2.44 (2H, m), 2.25 (3H, s), 16542.20
(8H, m), 1.66 (1H, m), 1.154140 (6H, m), 0.87 (3H, t, J:7.2
HZ); 13C NMR (75 MHZ, CDCl3) 6 146.50, 144.36, 143.79,
143.13, 128.52, 127.15, 67.05, 61.49, 56.86, 40.70, 36.07,
32.67, 31.76, 31.56, 29.27, 29.07, 23.39, 22.70, 14.27; Anal.
Calcd for C2OH33BrN2.0.3H2O: C, 62.10; H, 8.76; N, 7.24.
Found: C, 62.03; H, 8.88; N, 7.12.

To a stirred solution of (S)-nicotine (0.46 g, 2.8 mmol) in
AcOH (10 ml) Was added trans-1-bromo-oct-3-ene (1.37 g,
7.17 mmol). The mixture Was heated at re?ux for 3 days.
AcOH Was evaporated and the residue Was recrystallized in

ethyl acetate-CHCl3 to afford (S)-trans-3-(1-methyl-pyrroli

din-2-yl)-1-oct-3 -enyl-pyridinium bromide hydrobromide
salt (NONB-3t) (0.76 g, 62%) as hygroscopic White crystals:
1H NMR (300 MHZ, CDCl3) 6 11.55 (1H, s), 10.27 (1H, s),
9.46 (1H, d, J:7.5 HZ), 9.16 (1H, d, 1:57 HZ), 8.22 (1H, dd,
J:7.5, 5.7 HZ), 5.72 (1H, m), 5.41 (2H, m), 4.88 (2H, m),

3.98 (1H, m), 3.38 (1H, m), 2.94 (3H, s), 26042.90 (3H, m),
2.43 (3H, m), 1.86 (2H, m), 1.004125 (4H, m), 0.79 (3H, t,
J:7.2 HZ); 13C NMR (75 MHZ, CDCl3) 6 147.29, 146.41,
145.11,137.58, 134.31,128.44, 122.37, 67.18, 62.27, 56.04,
38.57, 34.49, 32.30, 32.00, 31.41, 22.32, 21.83, 14.12; Anal.
Calcd for Cl8H3OBr2N2.0.3H2O: C, 49.22; H, 6.93; N, 6.38.
Found: C, 49.25; H, 7.03; N, 6.30.

EXAMPLE 3

(S)-cis-3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-3 -enyl
pyridinium bromide hydrobromide salt (NONB -3 c)
20

DMF (18 mL) Was added triphenylphosphine (2.28 g, 8.69

EXAMPLE 2
25

S

1 D ec- 4 -eny l - 3 - 1 -methy 1 -pyrro11din- 2 -y l

-trans- -

-

pyridinium bromide (NDNB-4t)
2a. trans-Dec-4-en-1-ol

Sodium borohydride (0.60 g, 3.8 mmol) Was added in
portions to a stirred solution of trans-dec-4-enal (1.54 g, 10.0
mmol) in methanol (50 mL). The reaction Was stirred at
room temperature for 30 min folloWed by the addition of
saturated NH4Cl. Methanol Was evaporated and Water Was
added to the residue. The mixture Was extracted With ether

30

35

40

45

in DMF (25 mL) Was added triphenylphosphine (2.81 g,
10.7 mmol). The solution Was cooled to 00 C. and NBS (1.85
g, 10.4 mmol) Was added in portions. After stirring for 30
min at room temperature, the reaction Was quenched With

methanol (1 mL). The solution Was diluted With ether (100
mL), Washed With Water, saturated aqueous NaHCO3 and
brine successively. The organic layer Was dried and concen
trated. The residue Was puri?ed by ?ash chromatography on
silica gel, eluting With hexane to afford trans-l-bromo-dec
4-ene (1.60 g, 75%) as a colorless oil: 1H NMR (300 MHZ,

CDCl3) 6 5.49 (1H, m), 5.35 (1H, m), 3.42 (2H, t, 1:66 HZ),
2.15 (2H, m), 1.96 (4H, m), 1.29 (6H, m), 0.90 (3H, t, J:7.2
HZ); 3C NMR (75 MHZ, CDCl3) 6 132.36, 127.89, 33.61,
32.80, 32.73, 31.65, 31.14, 29.45, 22.82, 14.36.
2c. (S)-trans-1-Dec-4-enyl-3-(1-methyl-pyrrolidin-2-yl)-py
ridinium bromide (NDNB-4t)

50

55

NaHCO3, Water and brine successively and dried. Evapora

The residue Was puri?ed by ?ash chromatography on silica
gel, eluting With hexane to afford cis-1-bromo-oct-3-ene
(1.36 g, 91%) as a colorless oil: 1H NMR (300 MHZ, CDCl3)

31.12, 27.43, 22.64, 14.30.
3b. (S)-cis-3-(1-Methyl-pyrrolidin-2-yl)-1-oct-3-enyl-pyri
dinium bromide hydrobromide salt (NONB-3c)
To a stirred solution of (S)-nicotine (0.47 g, 2.9 mmol) in
AcOH (8 ml) Was added cis-1-bromo-oct-3-ene (1.34 g, 7.00
mmol). The mixture Was heated at re?ux for 3 days. AcOH
Was evaporated and the residue Was recrystalliZed in ethyl

acetate-CHCl3 to afford (S)-cis-3-(1-methyl-pyrrolidin-2
yl)-1-oct-3-enyl-pyridinium bromide hydrobromide salt
(NONB-3c) (0.62 g, 49%) as hygroscopic White crystals: 1H
NMR (300 MHZ, CDCl3) 6 12.19 (1H, s), 10.71 (1H, s), 9.74
(1H, d, 1:78 HZ), 8.74 (1H, d, 1:57 HZ), 8.16 (1H, dd,
1:78, 5.7 HZ), 5.79 (1H, m), 5.58 (1H, m), 5.40 (1H, m),
4.82 (2H, m), 4.01 (1H, m), 3.03 (1H, m), 2.94 (3H, d, 1:42
HZ), 2.204290 (5H, m), 1.87 (1H, m), 1.70 (2H, m),
1.0(L1.25 (4H, m), 0.79 (3H, t, J:7.2 HZ); 13C NMR (75
MHZ, CDCl3) 6 146.96, 146.29, 145.29, 136.33, 134.12,
128.37, 121.81, 67.09, 62.01, 55.92, 38.53, 31.94, 31.41,
29.34, 26.94, 22.18, 21.72, 14.04; Anal. Calcd for
Cl8H3OBr2N2.0.4H2O: C, 48.97; H, 7.03; N, 6.35. Found: C,
49.00; H, 7.36; N, 6.39.
EXAMPLE 4

(S)-cis-1-Dec-4-enyl-3 -(1-methyl-pyrrolidin-2-yl)
pyridinium bromide hydrobromide salt (NDNB -4c)
60

4a. cis-1-Bromo-dec-4-ene
To a solution of cis-dec-4-en-1-ol (1.00 g, 6.41 mmol) in

To a stirred solution of (S)-nicotine (0.47 g, 2.9 mmol) in
AcOH (15 ml) Was added trans-1-bromo-dec-4-ene (1.55 g,
7.08 mmol). The mixture Was heated at re?ux for 3 days.
AcOH Was evaporated and the residue Was dissolved in
CHCl3. The mixture Was Washed With saturated aqueous

nol (1 mL). The solution Was diluted With ether (100 mL),
Washed With Water, saturated aqueous NaHCO3 and brine
successively. The organic layer Was dried and concentrated.

6 5.53 (1H, m), 5.35 (1H, m), 3.36 (2H, t, J:7.2 HZ), 2.60

the next step Without further puri?cation: 1H NMR (300

2b. trans-1-Bromo-dec-4-ene
To a solution of trans-dec-4-en-1-ol (1.52 g, 9.74 mmol)

mmol). The solution Was cooled to 00 C. and NBS (1.50 g,
8.43 mmol) Was added in portions. After stirring for 30 min
at room temperature, the reaction Was quenched With metha

(2H, m), 2.04 (2H, m), 1.33 (4H, m), 0.89 (3H, t, 1:72 HZ);
3C NMR (75 MHZ, CDCl3) 6 133.27, 125.84, 32.93, 31.97,

and the combined organic layers Were Washed With Water
and dried. Evaporation of the solvent gave trans-dec-4-en
1-ol (1.52 g, 97%) as a pale yelloW oil, Which Was used in

MHZ, CDCl3) 6 5.39 (2H, m), 3.60 (2H, t, 1:66 HZ), 2.02
(5H, m), 1.56 (2H, m), 1.23 (6H, m), 0.84 (3H, t, 1:69 HZ);
13C NMR (75 MHZ, CDCl3) 6 131.31, 129.44, 62.66, 32.80,
32.70, 31.67, 29.51, 29.18, 22.82, 14.36.

3a. cis-1-Bromo-oct-3-ene
To a solution of cis-oct-3-en-1-ol (1.00 g, 7.81 mmol) in

DMF (15 mL) Was added triphenylphosphine (1.87 g, 7.13
65

mmol). The solution Was cooled to 00 C. and NBS (1.23 g,
6.91 mmol) Was added in portions. After stirring for 30 min
at room temperature, the reaction Was quenched With metha

nol (0.6 mL). The solution Was diluted With ether (60 mL),

US 7,091,357 B2
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Washed With Water, saturated aqueous NaHCO3 and brine
successively. The organic layer Was dried and concentrated.
The residue Was puri?ed by ?ash chromatography on silica
gel, eluting With hexane to a?‘ord cis-1-bromo-dec-4-ene
(1.23 g, 96%) as a colorless oil: 1H NMR (300 MHZ, CDCl3)

The residue Was puri?ed by ?ash chromatography on silica

gel, eluting With hexane to a?‘ord 10-bromo-dec-1-ene (1.38
g, 81%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6

5.80 (1H, m), 4.94 (2H, m), 3.38 (2H, t, 1:69 HZ), 2.02 (2H,
m), 1.83 (2H, m), 1.2(L1.55 (10H, m); 13C NMR (75 MHZ,
CDCl3)6139.17, 114.30, 34.29, 34.02, 33.06, 29.53, 29.25,

6 5.38 (1H, m), 5.29 (1H, m), 3.39 (2H, t, 1:69 HZ), 2.17

29.12, 28.96, 28.40.

(2H, m), 2.03 (2H, m), 1.88 (2H, m), 1.28 (6H, m), 0.87 (3H,
t, 1:66 HZ); 13C NMR (75 MHZ, CDCl3) 6 131.87, 127.39,
33.65, 32.90, 31.76, 29.63, 27.51, 25.87, 22.83, 14.35.
4b. (S)-cis-1-Dec-4-enyl-3-(1-methyl-pyrrolidin-2-yl)-pyri
dinium bromide hydrobromide salt (NDNB-4c)

6b.
(S)-1-Dec-9-enyl-3 -(1-methyl-pyrrolidin-2-yl)-pyri
dinium bromide (NDNB-9e)
To a stirred solution of (S)-nicotine (0.52 g, 3.2 mmol) in
AcOH (10 ml) Was added 10-bromo-dec-1-ene (1.66 g, 7.58
mmol). The mixture Was heated at re?ux for 3 days. AcOH

To a stirred solution of (S)-nicotine (0.35 g, 2.2 mmol) in
AcOH (10 ml) Was added cis-1-bromo-dec-4-ene (1.15 g,

Was evaporated and the residue Was dissolved in CHCl3. The
mixture Was Washed With saturated aqueous NaHCO3, Water

5.25 mmol). The mixture Was heated at re?ux for 3 days.
AcOH Was evaporated and the residue Was recrystallized in

ethyl acetate-CHCl3 to a?‘ord (S)-cis-1-dec-4-enyl-3-(1-me
thyl-pyrrolidin-2-yl)-pyridinium bromide hydrobromide salt
(NDNB-4c) (0.54 g, 54%) as hygroscopic White crystals: 1H
NMR (300 MHZ, CDCl3) 6 11.93 (1H, s), 10.75 (1H, s), 9.78
(1H, d, J:7.8 HZ), 8.69 (1H, d, 1:60 HZ), 8.20 (1H, dd,
1:78, 6.0 HZ), 5.88 (1H, m), 5.49 (1H, m), 5.30 (1H, m),
4.72 (2H, m), 4.01 (1H, m), 3.30 (1H, m), 2.97 (3H, d, 1:51
HZ), 2.73 (1H, m), 2.1(%2.60 (7H, m), 1.96 (2H, m), 1.70
(2H, in), 1.154140 (6H, m), 0.86 (3H, t, J:7.2 HZ); 13C
NMR (75 MHZ, CDCl3) 6 147.41, 146.38, 144.98, 134.68,
132.93, 128.93, 126.06, 67.20, 62.37, 56.07, 38.71, 32.00,
31.64, 31.38, 29.34, 27.61, 23.94, 22.74, 21.91, 14.32; Anal.
Calcd for C2OH34Br2N2.0.5H2O: C, 50.97; H, 7.49; N, 5.94.
Found: C, 50.90; H, 7.55; N, 5.94.

and brine successively and dried. Evaporation of the solvent
folloWed by titration With ether a?‘orded 0.74 g (61%) of

(S)-1-dec-9-enyl-3-(1-methyl-pyrrolidin-2-yl)-pyridinium
bromide (NDNB-9e) as a broWn oil. 1H NMR (300 MHZ,
20

25

EXAMPLE 7
30

EXAMPLE 5

(S)-3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-7-enyl-pyri
35

To a stirred solution of (S)-nicotine (0.12 g, 0.71 mmol)
in AcOH (2 ml) Was added 8-bromo-oct-1-ene (0.34 g, 1.8
mmol). The mixture Was heated at re?ux for 3 days. AcOH

and brine successively and dried. Evaporation of the solvent
folloWed by titration With ether a?‘orded 0.19 g (77%) of

40

45

7b. 11-Bromo-undec-1-ene
To a solution of undec-10-en-1-ol (0.86 g, 5.0 mmol) in

DMF (15 mL) Was added triphenylphosphine (1.46 g, 5.6
50

mmol). The solution Was cooled to 00 C. and NBS (0.96 g,
5.4 mmol) Was added in portions. After stirring for 30 min
at room temperature, the reaction Was quenched With metha

nol (0.5 mL). The solution Was diluted With ether (80 mL),
Washed With Water, saturated aqueous NaHCO3 and brine
successively. The organic layer Was dried and concentrated.
55

The residue Was puri?ed by ?ash chromatography on silica
gel, eluting With hexane to a?‘ord 11-bromo-undec-1-ene
(0.96 g, 82%) as a colorless oil: 1H NMR (300 MHZ, CDCl3)

6 5.79 (1H, m), 4.93 (2H, m), 3.38 (2H, t, 1:69 HZ), 2.02

dinium bromide (NDNB - 9e)

60

(2H, m), 1.83 (2H, in), 1.204155 (12H, m); 13C NMR (75
MHZ, CDCl3) 6 139.36, 114.33, 34.27, 33.99, 33.01, 29.57><
2, 29.27, 29.09, 28.94, 28.35.
7c. (S)-3-(1-Methyl-pyrrolidin-2-yl)-1-undec-10-enyl-pyri
dinium bromide (NUNB-10e)

DMF (18 mL) Was added triphenylphosphine (2.30 g, 8.77
mmol). The solution Was cooled to 00 C. and NBS (1.52 g,
8.54 mmol) Was added in portions. After stirring for 30 min
at room temperature, the reaction Was quenched With metha

nol (0.8 mL). The solution Was diluted With ether (80 mL),
Washed With Water, saturated aqueous NaHCO3 and brine
successively. The organic layer Was dried and concentrated.

and the ?ltrate Was concentrated in vacuo to dryness to give
undec-10-en-1-ol (0.86 g, 100%) as a colorless oil, Which
Was used in the next step Without further puri?cation: 1H

NMR (300 MHZ, CDCl3) 6 5.78 (1H, m), 4.92 (2H, m), 3.61
(2H, t, 1:66 HZ), 2.01 (2H, m), 1.53 (3H, in), 1.214140
(12H, m); 13C NMR (75 MHZ, CDCl3) 6 139.43, 114.31,
63.24, 34.00, 32.98, 29.74, 29.61, 29.31, 29.11, 25.92.

EXAMPLE 6

6a. 10-Bromo-dec-1-ene
To a solution of dec-9-en-1-ol (1.22 g, 7.82 mmol) in

A mixture of undec-10-yn-1 -ol (0.84 g, 5.0 mmol), quino
line (0.13 ml), Lindlar’s catalyst (100 mg, 17% W/W) and
EtOH (20 mL) Was hydrogenated in a Parr apparatus at 50

bromide (NONB-7e) as a broWn oil. 1H NMR (300 MHZ,

(S)-1-Dec-9-enyl-3-(1-methyl-pyrrolidin-2-yl)-pyri

pyridinium bromide (NUNB-10e)

psi of H2 for 1 h. The mixture Was ?ltered through Celite,

(S) -3 -(1-methyl-pyrrolidin-2-yl)-1-oct-7-enyl-pyridinium
CDCl3) 6 9.70 (1H, d, 1:60 HZ), 9.21 (1H, s), 8.41 (1H, d,
1:81 HZ), 8.08 (1H, dd, 1:81, 6.0 HZ), 5.72 (1H, in),
4.864510 (4H, m), 3.50 (1H, t, 1:84 HZ), 3.22 (1H, m),
2.41 (2H, m), 2.20 (3H, s), 1.8(L2.10 (6H, m), 1.61 (1H, m),
12041.44 (6H, m); 13C NMR (75 MHZ, CDCl3) 6 146.12,
144.00, 143.28, 142.63, 138.22, 128.05, 114.20, 66.68,
61.67, 56.48, 40.29, 35.67, 33.30, 31.88, 28.33, 28.27,
25.76, 22.98; Anal. Calcd for Cl8H29BrN2.0.35HBr: C,
56.65; H, 7.75; N, 7.34. Found: C, 56.96; H, 7.98; N, 6.95.

(S)-3 -(1-Methyl-pyrrolidin-2-yl)-1-undec-10-enyl
7a. Undec-10-en-1-ol

dinium bromide (NONB-7e)

Was evaporated and the residue Was dissolved in CHCl3. The
mixture Was Washed With saturated aqueous NaHCO3, Water

CDCl3) 6 9.65 (1H, d, 1:51 HZ), 9.14 (1H, s), 8.41(1H, d,
1:81 HZ), 8.09 (1H, dd, 1:81, 5.1 HZ), 5.75 (1H, in),
4.884510 (4H, m), 3.54 (1H, t, 1:81 HZ), 3.23 (1H, m),
2.45 (2H, m), 2.22 (3H, s), 1.7(L2.10 (6H, m), 1.61 (1H, m),
1.1(L1.40 (10H, m); 13C NMR (75 MHZ, CDCl3) 6 146.46,
144.39, 143.74, 142.97, 139.07, 128.50, 114.33, 67.17,
62.25, 56.92, 40.74, 36.11, 33.93, 32.35, 29.42, 29.24,
29.15, 29.03, 26.35, 23.41.
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To a stirred solution of (S)-nicotine (0.14 g, 0.86 mmol)
in AcOH (4 ml) Was added 11-bromo-undec-1-ene (0.50 g,
2.1 mmol). The mixture Was heated at re?ux for 3 days.
AcOH Was evaporated and the residue Was dissolved in
CHCl3. The mixture Was Washed With saturated aqueous
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NaHCO3, Water and brine successively and dried. Evapora

organic layer Was separated and the aqueous phase Was
extracted With ether. The combined organic layers Were
Washed With Water and brine and dried. Evaporation of the

tion of the solvent followed by titration With ether a?forded

0.22 g (67%) of (S)-3-(1-methyl-pyrrolidin-2-yl)-1-undec

solvent gave 6-cyclobutylidene-hexan-1-ol as a colorless oil,
Which Was used in the next step Without further puri?cation.

10-enyl-pyridinium bromide (NUNB-10e) as a broWn oil.

1H NMR (300 MZ, CDCl3) 6 9.61 (1H, d, J:5.7 HZ), 9.22
(1H, s), 8.40 (1H, d, 1:81 HZ), 8.08 (1H, dd, 1:81, 6.0 HZ),
5.77 (1H, m), 48545.10 (4H, m), 3.54 (1H, t, 1:81 HZ),
3.24 (1H, m), 2.43 (2H, m), 2.23 (3H, s), 18042.15 (6H, m),
1.63 (1H, m), 1.104144 (12H, m); 13C NMR (75 MHZ,
CDCl3) 6 146.43, 144.21, 143.65, 143.09, 139.05, 128.44,
114.16, 66.97, 62.02, 56.82, 40.62, 35.99, 33.88, 32.24,
29.44><2, 29.18><2, 28.98, 29.26, 23.33.

A solution of the foregoing product in MeOH (20 mL)
Was hydrogenated With PdiC (0.12 g, 10% W/W) in a Parr

apparatus at 50 psi of H2 overnight. The catalyst Was
removed by ?ltration, and the ?ltrate Was evaporated under
reduced pressure to give 6-cyclobutyl-hexan-1-ol (0.48 g,
88%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6 3.62

(2H, t, 1:66 HZ), 2.22 (1H, m), 2.03 (2H, m), 1.80 (2H, m),
1.55 (5H, m), 1.104140 (8H, m); 13C NMR (75 MHZ,
CDCl3) 6 63.28, 37.25, 36.42, 33.05, 29.71, 28.68, 27.40,

EXAMLE 8

26.04, 18.78.

(S)-1-(6-Cyclobutyl-hexyl)-3 -(1-methyl-pyrrolidin

8d. (6-Bromo-hexyl)-cyclobutane

2-yl)pyridinium bromide hydrobromide salt

To a solution of 6-cyclobutyl-hexan-1-ol (0.47 g, 3.0

(NCyNB-4)

mmol) in DMF (10 mL) Was added triphenylphosphine
(0.88 g, 3.4 mmol). The solution Was cooled to 00 C. and

8a. 6-Oxo-hexanoic acid methyl ester

20

for 30 min at room temperature, the reaction Was quenched

A solution of e-caprolactone (11.4 g, 0.100 mol), MeOH
(300 mL) and concentrated HZSO4 (5 mL) Was re?uxed

With methanol (0.5 mL). The solution Was diluted With ether

overnight. The resulting mixture Was cooled to room tem
perature and concentrated. Water Was added to the residue

and the pH Was adjusted to 7 With solid NaHCO3. The
aqueous layer Was extracted With ether. The combined
organic layers Were Washed With Water, dried and concen
trated to give 6-hydroxy-hexanoic acid methyl ester as a
colorless oil, Which Was used in the next step Without further

puri?cation.
The foregoing crude product Was dissolved in CH2Cl2
(300 mL). Sodium acetate (2.6 g, 32 mmol) and PCC (32.7

25

30

g, 50 mmol) Was added. After being stirred at room tem
35

ethyl acetate-CHCl3 to afford (S)-1-(6-cyclobutyl-hexyl)-3
(1-methyl-pyrrolidin-2-yl)-pyridinium bromide hydrobro

MHZ, CDCl3) 6 9.72 (1H, t, 1:15 HZ), 3.62 (3H, s), 2.43
40

8b. 6-Cyclobutylidene-hexanoic acid methyl ester
To a stirred suspension of KOtBu (4.81 g, 42.8 mmol) in
21.9 mmol). The resulting mixture Was re?uxed for 15 min

45

and alloWed to cool to room temperature. A solution of

6-oxo-hexanoic acid methyl ester (3.14 g, 21.8 mmol) in
tBuOMe (5 mL) Was added quickly and the resulting mix
ture Was stirred overnight. Water (30 mL) Was added. The
aqueous phase Was extracted With hexane. The combined

50

organic phases Were Washed With saturated aqueous NH4Cl
and brine and dried. Concentration and puri?cation of the
residue by ?ash chromatography on silica gel (hexanezethyl

MHZ, CDCl3) 6 5.00 (1H, m), 3.64 (3H, s), 2.60 (4H, m),
2.28 (2H, t, 1:78 HZ), 1.88 (4H, m), 1.60 (2H, m), 1.32 (2H,
m); 13C NMR (75 MHZ, CDCl3) 6 174.25, 140.29, 119.88,
51.66, 34.23, 31.09, 29.47, 29.44, 27.75, 24.76, 17.28.
8c. 6-Cyclobutyl-hexan-1-ol

added to the reaction mixture. After stirmg for 1 h, the

crystals: 1H NMR (300 MHZ, CDCl3) 6 11.64 (1H, s), 10.42
(1H, s), 9.54 (1H, d, 1:81 HZ), 9.06 (1H, d, 1:60 HZ), 8.27
(1H, dd, 1:81, 6.0 HZ), 5.74 (1H, m), 4.78 (2H, m), 3.98
(1H, m), 3.34 (1H, m), 2.96 (3H, d, 1:51 HZ), 2.73 (1H, m),
2.44 (3H, m), 2.14 (3H, m), 1.96 (2H, m), 1.75 (2H, m), 1.51
(2H, m), 1.33 (6H, m), 1.16 (2H, m); 13C NMR (75 MHZ,
CDCl3) 6 147.61, 146.61, 144.67, 134.77, 128.91, 67.09,
63.07, 56.09, 38.71, 36.99, 36.17, 32.06, 31.76, 29.20,
28.60, 27.14, 26.53, 21.89, 18.72; Anal. Calcd for
C2OH34Br2N2.0.1H2O: C, 51.56; H, 7.44; N, 6.01. Found: C,
51.70; H, 7.45; N, 5.96.

(S)-1-(6-Cyclopentyl-hexyl)-3-(1-methyl-pyrrolidin
55

2-yl)-pyridinium bromide hydrobromide salt

(NCyNB-5)

60

To a stirred solution of 6-cyclobutylidene-hexanoic acid

methyl ester (0.60 g, 3.3 mmol) in toluene (30 mL) Was
added DlBAL-H (8.2 mL, 1 M solution in hexane, 8.2
mmol) dropWise at 0° C. under N2. After stirring at 0° C. for
30 min, the reaction Was quenched by MeOH (3 mL).
Saturated aqueous sodium potassium tartrate (20 mL) Was

mide salt (NCyNB4) (0.31 g, 61%) as hygroscopic White

EXAMPLE 9

acetate, 10:1) a?forded 6-cyclobutylidene-hexanoic acid
methyl ester (1.27 g, 32%) as a colorless oil: 1H NMR (300

AcOH (4 ml) Was added (6-bromo-hexyl)cyclobutane (0.59
g, 2.7 mmol). The mixture Was heated at re?ux for 3 days.
AcOH Was evaporated and the residue Was recrystalliZed in

(80*84° C. at 0.2 mmHg) to give 6-oxo-hexanoic acid
methyl ester (8.58 g, 60%) as a colorless oil: 1H NMR (300

tert-butyl methyl ether (tBuOMe) (50 mL) Was added
(4-bromobutyl)triphenylphosphonium bromide (10.45 g,

NMR (300 MHZ, CDCl3) 6 3.40 (2H, t, 1:69 HZ), 2.23 (1H,
m), 2.02 (2H, m), 1.82 (4H, m), 1.55 (2H, m), 1.12*1.46
(8H, m); 13C NMR (75 MHZ, CDCl3) 6 37.19, 36.39, 34.40,
33.11, 29.07, 28.68, 28.51, 27.26, 18.80.
8e. (S)-1-(6-Cyclobutyl-hexyl)-3-(1—methyl-pyrrolidin-2
To a stired solution of (S)-nicotine (0.18 g, 1.1 mmol) in

mixture Was ?ltered through Florisil, and the ?ltrate Was

(2H, m), 2.29 (2H, m), 1.62 (4H, m); 13C NMR (75 MHZ,
CDCl3) 6 201.99, 173.64, 51.73, 43.66, 33.88, 24.53, 21.69.

(60 mL), Washed With Water, saturated aqueous NaHCO3
and brine successively. The organic layer Was dried and
concentrated. The residue Was puri?ed by ?ash chromatog
raphy on silica gel, eluting With hexane to afford (6-bromo
hexyl)-cyclobutane (0.60 g, 91%) as a colorless oil: 1H

yl)-pyridinium bromide hydrobromide salt (NCyNB-4)

perature for 2 h, ether (2000 mL) Was added, the reaction
concentrated. The residue Was distilled at reduced pressure

NBS (0.57 g, 3.2 mmol) Was added in portions. After stirring

9a. 6-Cyclopentylidene-hexanoic acid methyl ester
To a stirred suspension of cyclopentyltriphenylphospho
nium bromide (10.0 g, 23.8 mmol) in TMF (60 mL) Was
added dropWise n-BuLi (10.2 mL, 2.5 M solution in hex
anes, 23.8 mmol) at 0° C. under N2. The resulting solution
Was stirred at this temperature for 30 min and cooled to —78
° C. A solution of 6-oxo-hexanoic acid methyl ester (3.33 g,

65

23.1 mmol) in THF (6 mL) Was added quickly. The resulting
mixture Was then alloWed to Warm to room temperature and

stirred overnight. Water (30 mL) Was added. The aqueous
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phase Was extracted With hexane. The combined organic
phases Were Washed With saturated aqueous NH4Cl and
brine and dried. Concentration and puri?cation of the resi

1.154160 (12H, m), 1.02 (2H, m); 13c NMR (75 MHZ,
CDC13) 6 147.78, 146.78, 144.41, 134.94, 128.90, 67.03,
63.14, 56.10, 40.26, 38.72, 36.23, 32.96, 32.11, 31.82,

due by ?ash chromatography on silica gel (hexane:ethyl
acetate, 10:1) a?forded 6-cyclopentylidene-hexanoic acid

5

methyl ester (3.15 g, 70%) as a colorless oil: 1H NMR (300

MHZ, CDCl3) 6 5.20 (1H, m), 3.64 (3H, s), 2.29 (2H, m),
2.16 (4H, m), 1.96 (2H, m), 1.62 (6H, m), 1.35 (2H, m); 13C
NMR (75 MHZ, CDCl3) 6 174.26, 143.54, 119.65, 51.66,
34.29, 33.79, 29.44, 28.86, 26.69, 26.61, 24.91.
9b. 6-Cyclopentylidene-hexan-1-ol

EXAMPLE 10

(S)-1-(6-Cyclohexyl-hexyl)-3 -(1-methyl-pyrrolidin
2-yl)-pyridinium bromide hydrobromide salt

(NCyNB-6)

To a stirred solution of 6-cyclopentylidene-hexanoic acid

methyl ester (2.77 g, 14.1 mmol) in toluene (130 mL) Was
added DlBAL-H (35.3 mL, 1 M solution in hexane, 35.3
mmol) dropWise at 0° C. under N2. After sting at 0° C. for
30 min, the reaction Was quenched by MeOH (10 mL).
Saturated aqueous sodium potassium tartrate (80 mL) Was
added to the reaction mixture. After stirring for 1 h, the
organic layer Was separated and the aqueous phase Was
extracted With ether. The combined organic layers Were
Washed With Water and brine and dried. Evaporation of the

10a. 6-Cyclohexylidene-hexanoic acid methyl ester
To a stirred suspension of cyclohexyltriphenylphospho
nium bromide (8.40 g, 19.8 mmol) in THF (50 mL) Was
added dropWise n-BuLi (8.70 mL, 2.5 M solution in hex
anes, 21.8 mmol) at 0° C. under N2. The resulting solution
Was stired at this temperature for 30 min and cooled to —78°
20

mixture Was then alloWed to Warm to room temperature and

as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6 5.24 (1H,

Asolution of 6-cyclopentylidene-hexan-1-ol (1.15 g, 6.85
mmol) in MeOH (50 mL) Was hydrogenated With Pd4C
(0.25 g, 10% W/W) in a Parr apparatus at 50 psi of H2
overnight. The catalyst Was removed by ?ltration, and the

25

1.424164 (6H, m), 12041.40 (8H, m), 1.04(2H, m); 13C
NMR (75 MHZ, CDCl3) 6 63.28, 40.41, 36.43, 33.06, 33.00,

methyl ester (2.02 g, 49%) as a colorless oil: 1H NMR (300
30

35

To a solution of 6-cyclopentyl-hexan-1-ol (1.20 g, 7.06

40

stirring for 30 min at room temperature, the reaction Was

oil: 1H NMR (300 MHZ, CDCl3) 6 3.40 (2H, t, J:6.9 HZ),
1.85 (2H, m), 1.73 (3H, m), 13841.64 (6H, in), 1.244138

(6H, m), 1.04 (2H, m); 13C NMR (75 MHZ, CDCl3) 6 40.38,
36.37, 34.35, 33.12, 32.99, 29.33, 28.87, 28.49, 25.46.
9e. (S)-1-(6-Cyclopentyl-hexyl)-3-(1—methyl-pyrrolidin-2
yl)-pyridinium bromide hydrobromide salt (NCyNB-5)

45

liZed in ethyl acetate-CHCl3 to afford (S)-1-(6-cyclopentyl

26.89, 24.79.
10b. 6-Cyclohexylidene-hexan- 1 -ol

methyl ester (1.28 g, 6.10 mmol) in toluene (60 mL) Was
added DlBAL-H (15.3 mL, 1 M solution in hexane, 15.3
mmol) dropWise at 0° C. under N2. After stirring at 0° C. for
30 min, the reaction Was quenched by MeOH (5 mL).
Saturated aqueous sodium potassium tartrate (40 mL) Was

solvent gave 6-cyclohexylidene-hexan-1-ol (1.12 g, 100%)
as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6 5.05 (1H,

50
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To a stirred solution of (S)-nicotine (0.43 g, 2.6 mmol) in
AcOH (10 ml) Was added (6-bromo-hexyl)-cyclopentane
(1.50 g, 6.44 mmol). The mixture Was heated at re?ux for 3
days. AcOH Was evaporated and the residue Was recrystal

hexyl) -3 -( 1 —methyl -pyrrolidin-2 -yl)-pyridinium bromide
hydrobromide salt (NCyNB-5) (0.68 g, 54%) as hygroscopic
White crystals: 1H NMR (300 MHZ, CDCl3) 6 11.74 (1H, s),
10.52 (1H, s), 9.62 (1H, d, 1:84 HZ), 8.99 (1H, d, 1:60 HZ),
8.29 (1H, dd, 1:78, 6.3 HZ), 5.80 (1H, m), 4.78 (2H, m),
4.01 (1H, m), 3.35 (1H, m), 2.98 (3H, d, 1:51 HZ), 2.76
(1H, m), 2.45 (3H, m), 2.15 (2H, m), 1.70 (3H, m),

(2H, m), 2.03 (6H, m), 1.61 (2H, in), 1.414154 (6H, m),
1.34 (2H, m); 13C NMR (75 MHZ, CDCl3) 6 174.26, 140.05,
120.82, 51.66, 37.40, 34.26, 29.89, 28.93, 28.08, 27.20,

added to the reaction mixture. After string for 1 h, the
organic layer Was separated and the aqueous phase Was
extracted With ether. The combined organic layers Were
Washed With Water and brine and dried. Evaporation of the

(2.08 g, 7.93 mmol). The solution Was cooled to 00 C. and
NBS (1.36 g, 7.64 mmol) Was added in portions. After

quenched With methanol (1 mL). The solution Was diluted
With ether (100 mL), Washed With Water, saturated aqueous
NaHCO3 and brine successively. The organic layer Was
dried and concentrated. The residue Was puri?ed by ?ash
chromatography on silica gel, eluting With hexane to afford
(6-bromo-hexyl)-cyclopentane (1.55 g, 94%) as a colorless

MHZ, CDCl3) 6 5.03 (1H, t, 1:66 HZ), 3.64 (3H, s), 2.29

To a stired solution of 6-cyclohexylidene-hexanoic acid

29.98, 29.04, 26.05, 25.47.
9d. (6-Bromo-hexyl)-cyclopentane
mmol) in DMF (20 mL) Was added triphenylphosphine

stirred overnight. Water (30 mL) Was added. The aqueous
phase Was extracted With hexane. The combined organic
phases Were Washed With saturated aqueous NH4Cl and
brine and dried. Concentration and puri?cation of the resi

due by ?ash chromatography on silica gel (hexane:ethyl
acetate, 10:1) afforded 6-cyclohexylidene-hexanoic acid

?ltrate Was evaporated under reduced pressure to give
6-cyclopentyl-hexan-1-ol (1.30 g, 100%) as a colorless oil:

1H NMR (300 MHZ, CDCl3) 6 3.63 (2H, t, 1:66 HZ),

C. A solution of 6-oxo-hexanoic acid methyl ester (2.84 g,

19.7 mmol) in THF (6 mL) Was added quickly. The resulting

solvent gave 6-cyclopentylidene-hexan-1-ol (2.47 g, 98%)

m), 3.63 (2H, t, 1:66 HZ), 2.21 (4H, m), 1.97 (2H, m),
15041.70 (6H, m), 1.34 (2H, m); 13C NMR (75 MHZ,
CDCl3) 6 143.28, 120.08, 63.22, 33.82, 33.00, 29.81, 29.75,
28.87, 26.72, 26.63, 25.73.
9c. 6-Cyclopentyl-hexan-1-ol

29.48, 28.77, 26.55, 25.43, 21.89; Anal. Calcd for
C2lH36Br2N2.0.2H2O: c, 52.55, H, 7.64; N, 5.84. Found: c,
52.41, H, 7.56; N, 5.78.

m), 3.62 (2H, t, 1:66 HZ), 2.05 (6H, in), 1.424164 (8H, m),
1.34 (2H, m); 13C NMR (75 MHZ, CDCl3) 6 139.78, 121.25,
63.22, 37.43, 32.96, 30.22, 28.96, 28.11, 27.23, 25.58.
10c. 6-Cyclohexyl-hexan-1-ol
A solution of 6-cyclohexylidene-hexan-1-ol (1.05 g, 5.77
mmol) in MEOH (40 mL) Was hydrogenated With Pd4C
(0.23 g, 10% W/W) in a Parr apparatus at 50 psi of H2
overnight. The catalyst Was removed by ?ltration, and the
?ltrate Was evaporated under reduced pressure to give
6-cyclohexyl-hexan-1-ol (1.02 g, 96%) as a colorless oil: 1H

NMR (300 MHZ, CDCl3) 6 3.63 (2H, t, 1:66 HZ), 1.464180
60

(7H, m), 10441.44 (12H, m), 0.86 (2H, m); 13C NMR (75
MHZ, CDCl3) 6 63.33, 37.92, 37.74, 33.72, 33.08, 30.04,
27.10, 27.04, 26.73, 26.05.
10d. (6—Bromo-hexyl)-cyclohexane
To a solution of 6-cyclohexyl-hexan-1-ol (0.98 g, 5.3

mmol) in DMF (15 mL) Was added triphenylphosphine
65

(1.56 g, 5.9 mmol). The solution Was cooled to 0° C. and

NBS (1.02 g, 5.7 mmol) Was added in portions. After stirring
for 30 min at room temperature, the reaction Was quenched
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With methanol (0.6 mL). The solution Was diluted With ether

2.22 (3H, s), 2.01 (2H, m), 1.89 (2H, m), 1.64 (2H, m), 1.28
(4H, m), 0.82 (3H, 1, 1:72 HZ); 13C NMR (75 MHZ, CDC13)
6 145.97, 144.38, 144.10, 143.57, 128.00, 86.12, 74.07,
67.30, 60.72, 56.92, 40.74, 36.11, 30.94, 23.14, 22.50,
22.16, 18.54, 13.80; Anal. Calcd for Cl8H27BrN2.0.5H2O:
c, 60.00; H, 7.83; N, 7.77. Found: c, 60.15; H, 7.92, N,

(80 mL), Washed With Water, saturated aqueous NaHCO3
and brine successively. The organic layer Was dried and
concentrated. The residue Was puri?ed by ?ash chromatog
raphy on silica gel, eluting With hexane to a?‘ord (6-bromo
hexyl)-cyclohexane (1.16 g, 89%) as a colorless oil: 1H

6.92.

NMR (300 MHZ, CDCl3) 6 3.41 (2H, t, J:7.2 HZ), 1.85 (2H,
m), 1.66 (5H, m), 1.42 (2H, m), 1.084136 (10H, m), 0.88
(2H, m); 13C NMR (75 MHZ, CDCl3) 6 37.91, 37.68, 34.37,
33.72, 33.14, 29.39, 28.51, 27.04, 26.96, 26.73.
10e. (S)-1-(6-Cyclohexyl-hexyl)-3 -(1-methyl-pyrrolidin-2
yl)-pyridinium bromide hydrobromide salt (NCyNB-6)

EXAMPLE 12

(S)-1-Dec-3 -ynyl-3-(1-methyl-pyrrolidin-2-yl)-pyri
dinium bromide (NDNB -3y)

To a stirred solution of (S)-nicotine (0.31 g, 1.9 mmol) in
AcOH (8 ml) Was added (6-bromo-hexyl)-cyclohexane

12a. 1-bromo-dec-3-yne

(1.15 g, 4.65 mmol). The mixture Was heated at re?ux for 3
days. AcOH Was evaporated and the residue Was recrystal

To a solution of dec-3-yn-1-ol (1.54 g, 10.0 mmol) in
DMF (25 mL) Was added triphenylphosphine (2.92 g, 11.2

liZed in ethyl acetate-CHCl3 to a?‘ord (S)-1-(6-cyclohexyl

mmol). The solution Was cooled to 00 C. and NBS (1.92 g,
10.8 mmol) Was added in portions. After stirring for 30 min
at room temperature, the reaction Was quenched With metha

hexyl) -3 -( 1 -methyl -pyrrolidin-2 -yl)-pyridinium bromide
hydrobromide salt (NCyNB-6) (0.59 g, 63%) as hygroscopic
White crystals: 1H NMR (300 MHZ, CDCl3) 6 11.71 (1H, s),
10.44 (1H, s), 9.58 (1H, d, 1:81 HZ), 9.04 (1H, d, 1:60 HZ),
8.29 (1H, dd, 1:78, 6.0 HZ), 5.75 (1H, m), 4.78 (2H, m),
4.02 (1H, m), 3.37 (1H, m), 2.98 (3H, d, 1:48 HZ), 2.75
(1H, m), 2.48 (3H, m), 2.13 (2H, m), 1.65 (5H, m),
10541.45 (12H, m), 0.83 (2H, m), 13C NMR (75 MHZ,
CDCl3) 6 147.66, 146.65, 144.57, 134.85, 128.93, 67.09,
63.11, 56.09, 38.71, 37.77, 37.52, 33.61, 32.09, 31.80,
29.53, 26.92, 26.84, 26.63, 26.54, 21.89; Anal. Calcd for
C22H38Br2N2.0.3H2O: C, 53.30; H, 7.85; N, 5.65. Found: C,
53.35; H, 7.74; N, 5.70.

nol (1 mL). The solution Was diluted With ether (150 mL),
Washed With Water, saturated aqueous NaHCO3 and brine
successively. The organic layer Was dried and concentrated.
The residue Was puri?ed by ?ash chromatography on silica
25

30

EXAMPLE 11

(S)-3 -(1-Methyl-pyrrolidin-2-yl)-1-oct-3 -ynyl-pyri
dinium bromide (NONB-3y)

35

40

45

gel, eluting With hexane to a?‘ord 1-bromo-oct-3-yne (1.35
g, 71%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6
50

55

CDCl3) 6 9.77 (1H, d, 1:57 HZ), 9.14 (1H, s), 8.43 (1H, d,
1:81 HZ), 8.04 (1H, dd, 1:81, 5.7 HZ), 5.16 (2H, m), 3.52
(1H, t, 1:81 HZ), 3.27 (1H, m), 3.03 (2H, m), 2.47 (2H, m),
2.26 (3H, s), 18542.10 (4H, m), 1.70 (1H, m), 1.15*1.45
(8H, m), 0.86 (3H, t, J:7.2 HZ); 13C NMR (75 MHZ, CDCl3)
6 145.91, 144.24, 144.12, 143.57, 128.02, 86.16, 73.98,
67.24, 60.66, 56.87, 40.70, 36.05, 31.44, 28.86, 28.75,
23.36, 22.71, 22.45, 18.82, 14.27; Anal. Calcd for
C2OH31BrN2.0.7H2O: C, 61.28; H, 8.33; N, 7.15. Found: C,
61.14; H, 8.21; N, 7.14.

(S)-1-(7-Methyl-oct-6-enyl)-3-(1—methyl-pyrrolidin
2-yl)-pyridinium bromide hydrobromide (NONB

6e7M)
60

and brine successively and dried. Evaporation of the solvent
folloWed by titration With ether a?‘orded 0.50 g (56%) of

(S) -3 -(1-methyl-pyrrolidin-2-yl)-1-oct-3 -ynyl-pyridinium
bromide (NONB-3y) as a broWn oil. 1H NMR (300 MHZ,

CDCl3) 6 9.74 (1H, d, 1:51 HZ), 9.15 (1H, s), 8.43 (1H, d,
1:78 HZ), 8.04 (1H, dd, 1:78, 5.1 HZ), 5.13 (2H, m), 3.51
(1H, t, 1:78 HZ), 3.23 (1H, m), 3.00 (2H, m), 2.42 (2H, m),

(S)-1-dec-3-ynyl-3 -(1-methyl-pyrrolidin-2-yl)-pyridinium

EXAMPLE 13

To a stirred solution of (S)-nicotine (0.41 g, 2.5 mmol) in
AcOH (10 ml) Was added 1-bromo-oct-3-yne (1.16 g, 6.14
mmol). The mixture Was heated at re?ux for 3 days. AcOH
Was evaporated and the residue Was dissolved in CHCl3. The
mixture Was Washed With saturated aqueous NaHCO3, Water

mmol). The mixture Was heated at re?ux for 3 days. AcOH
Was evaporated and the residue Was dissolved in CHCl3. The
mixture Was Washed With saturated aqueous NaHCO3, Water

bromide (NDNB-3y) as a broWn oil. 1H NMR (300 MHZ,

The residue Was puri?ed by ?ash chromatography on silica

3.40 (2H, d, J:7.2 HZ), 2.78 (2H, m), 2.15 (2H, m), 1.22
(4H, m), 0.88 (3H, t, 1:69 HZ); 13C NMR (75 MHZ, CDCl3)
6 82.83, 77.05, 31.18, 30.63, 23.68, 22.20, 18.67, 13.89.
11b.
(S)-3-(1-Methyl-pyrrolidin-2-yl)-1-oct-3-ynyl-pyri
dinium bromide (NONB-3y)

3.40 (2H, d, J:7.2 HZ), 2.70 (2H, m), 2.14 (2H, m),
1.2(L1.55 (8H, m), 0.88 (3H, t, 1:69 HZ); 13C NMR (75
MHZ, CDCl3) 6 82.89, 77.05, 31.62, 30.68, 29.06, 28.78,
23.65, 22.86, 18.99, 13.38.
12b. (S)-1-Dec-3 -ynyl-3 -(1-methyl-pyrrolidin-2-yl)-pyri
dinium bromide Q\IDNB-3y)

and brine successively and dried. Evaporation of the solvent
folloWed by titration With ether a?‘orded 0.55 g (51%) of

at room temperature, the reaction Was quenched With metha

nol (1 mL). The solution Was diluted With ether (150 mL),
Washed With Water, saturated aqueous NaHCO3 and brine
successively. The organic layer Was dried and concentrated.

g, 72%) as a colorless oil: 1H NMR (300 MHZ, CDCl3) 6

To a stirred solution of (S)-nicotine (0.46 g, 2.8 mmol) in
AcOH (15 ml) Was added 1-bromo-dec-3-yne (1.50 g, 6.91

11a. 1-Bromo-oct-3-yne
To a solution of oct-3-yn-1-ol (1.26 g, 10.0 mmol) in
DMF (25 mL) Was added triphenylphosphine (2.92 g, 11.2
mmol). The solution Was cooled to 00 C. and NBS (1.92 g,
10.8 mmol) Was added in portions. After stirring for 30 min

gel, eluting With hexane to a?‘ord 1-bromo-dec-3-yne (1.57
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13a. 7-Methyl-oct-6-enoic acid methyl ester
To a stirred suspension of isopropyltriphenylphospho
nium bromide (10.9 g, 28.3 mmol) in THF (60 mL) Was
added dropWise n-BuLi (12.0 mL, 2.5 M solution in hex
anes, 30.0 mmol) at 0° C. under N2. The resulting solution
Was stirred at this temperature for 30 min and cooled to —78°

C. A solution of 6-oxo-hexanoic acid methyl ester (3.95 g,
19.7 mmol) in THF (10 mL) Was added quickly. The

US 7,091,357 B2
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resulting mixture Was then allowed to Warm to room tem

EXAMPLE 14

perature and stirred overnight. Water (30 mL) Was added.

(S)-1-(7-Methyl-octyl)-3 -(1-methyl-pyrrolidin-2-yl)

The aqueous phase Was extracted With hexane. The com

bined organic phases Were Washed With saturated aqueous
NH4Cl and brine and dried. Concentration and puri?cation

pyridinium bromide hydrobromide salt (NONB

7M)

5

of the residue by ?ash chromatography on silicagel (hexane:

ethyl acetate, 10:1) a?forded 7-methyl-oct-6-enoic acid

14a. 7-Methyl-octan-1-ol
A solution of7-methyl-oct-6-en-1-ol (1.42 g, 10.0 mmol)
in MeOH (70 mL) Was hydrogenated With PdiC (0.40 g,

methyl ester (3.39 g, 72%) as a colorless oil: 1H NMR (300

MHZ, CDCl3) 6 5.08 (1H, m), 3.64 (3H, s), 2.29 (2H, t, J:7.2
HZ), 1.97 (2H, m), 1.66 (3H, s), 1.62 (2H, m), 1.58 (3H, s),
1.36 (2H, m); 13C NMR (75 MHZ, CDCl3) 6 174.26, 140.05,
131.80, 124.27, 51.67, 34.29, 29.60, 27.89, 25.97, 24.87,

10% W/W) in a Parr apparatus at 50 psi of H2 overnight. The
catalyst Was removed by ?ltration, and the ?ltrate Was

17.94.

evaporated under reduced pressure to give 7-methyl-octan

13b. 7-Methyl-oct-6-en-1-ol

CDCl3) 6 3.64 (2H, t, 1:66 HZ), 1.54 (3H, m), 1.104144

To a stirred solution of 7-methyl-oct-6-enoic acid methyl
ester (3.29 g, 19.4 mmol) in toluene (180 mL) Was added
DlBAL-H (48.5 mL, 1 M solution in hexane, 48.5 mmol)
dropWise at 0° C. under N2. After stirring at 0° C. for 30 min,
the reaction Was quenched by MeOH (12 mL). Saturated
aqueous sodium potassium tartrate (120 mL) Was added to
the reaction mixture. After stirring for 1 h, the organic layer

(8H, m), 0.88 (3H, s), 0.85 (3H, s); 13C NMR (75 MHZ,
CDCl3) 6 63.28, 39.21, 33.06, 29.98, 28.24, 27.64, 26.06,

Was separated and the aqueous phase Was extracted With
ether. The combined organic layers Were Washed With Water
and brine and dried. Evaporation of the solvent gave 7-me
thyl-oct-6-en-1-ol (2.70 g, 98%) as a colorless oil: 1H NMR

(300 MHZ, CDCl3) 6 5.11 (1H, m), 3.63 (2H, m), 1.99 (2H,
m), 1.68 (3H, s), 1.59 (3H, s), 1.53 (2H, m), 12541.45 (4H,
m); 13C NMR (75 MHZ, CDCl3) 6 131.52, 124.69, 63.25,
33.00, 29.95, 28.25, 26.02, 25.69, 17.98.
13c. 8-Bromo-2-methyl-oct-2-ene

1-ol (1.38 g, 96%) as a colorless oil: 1H NMR (300 MHZ,

22.94.
20

9.26 mmol). The solution Was cooled to 0° C. and NBS (1.60
g, 8.99 mmol) Was added in portions. After stirring for 30
min at room temperature, the reaction Was quenched With
25

30

To a solution of 7-methyl-oct-6-en-1-ol (1.00 g, 7.04

mmol) in DMF (18 mL) Was added triphenylphosphine
(2.06 g, 7.85 mmol). The solution Was cooled to 00 C. and
NBS (1.35 g, 7.58 mmol) Was added in portions. After
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stirring for 30 min at room temperature, the reaction Was

quenched With methanol (1 mL). The solution Was diluted
With ether (100 mL), Washed With Water, saturated aqueous
NaHCO3 and brine successively. The organic layer Was
dried and concentrated. The residue Was puri?ed by ?ash
chromatography on silica gel, eluting With hexane to afford
8-bromo-2-methyl-oct-2-ene (1.11 g, 77%) as a colorless

oil: 1H NMR (300 MHZ, CDCl3) 6 5.10 (1H, m), 3.40 (2H,
t, 1:69 HZ), 1.98 (2H, m), 1.86 (2H, m), 1.68 (3H, d, 1:09
HZ), 1.60 (3H, d, 1:03 HZ), 1.42 (2H, m), 1.41 (4H, m); 13C
NMR (75 MHZ, CDCl3) 6 132.08, 124.81, 34.59, 33.44,
29.64, 28.49, 28.44, 26.36, 18.35.
13d. (S)-1-(7-Methyl-oct-6-enyl)-3-(1-methyl-pyrrolidin-2

yl)-pyridinium bromide hydrobromide (NONB-6e7M)

CDCl3) 6 3.41 (2H, t, 1:66 HZ), 1.85 (2H, m), 1.52 (1H, m),
1.42 (2H, m), 1.28 (4H, m), 1.17 (2H, m), 0.87 (3H, s), 0.85
(3H, s); 13C NMR (75 MHZ, CDCl3) 6 39.16, 34.34, 33.14,
29.34, 28.52, 28.24, 27.51, 22.94.
14c. (S)-1-(7-Methyl-octyl)-3-(1-methyl-pyrrolidin-2-yl)
pyridinium bromide hydrobromide salt (NONB-7M)
To a stirred solution of (S)-nicotine (0.37 g, 2.3 mmol) in

40
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5.80 mmol). The mixture Was heated at re?ux for 3 days.
AcOH Was evaporated and the residue Was recrystalliZed in

ethyl acetate-CHCl3 to (S)-1-(7-methyl-octyl)-3-(1-methyl
pyrrolidin-2-yl)-pyridinium bromide hydrobromide salt
(NONB-7M) (0.60 g, 58%) as hygroscopic White crystals:
1H NMR (300 MHZ, CDCl3) 6 11.85 (1H, s), 10.61 (1H, s),
9.68 (1H, d, 1:84 HZ), 8.83 (1H, d, 1:60 HZ), 8.24 (1H, dd,
1:81, 6.3 HZ), 5.80 (1H, m), 4.75 (2H, m), 4.01 (1H, m),
3.32 (1H, m), 2.96 (3H, d, 1:48 HZ), 2.74 (1H, m),
2.3(%2.60 (3H, m), 2.11 (2H, m), 1.054155 (9H, m), 0.82
(6H, d, 1:66 HZ); 13C NMR (75 MHZ, CDCl3) 6 147.64,
146.61, 144.97, 134.71, 129.09, 67.21, 63.13, 56.16, 38.97,
32.15, 31.82, 29.48, 28.10, 27.36, 26.55, 22.86, 21.97; Anal.
Calcd for Cl9H34Br2N2.0.3H2O: C, 50.09; H, 7.63; N, 6.15.
Found: C, 50.08; H, 7.64; N, 6.13.
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EXAMPLE 15

mide (NONB-6e7M) (0.58 g, 63%) as hygroscopic White

crystals: 1H NMR (300 MHZ, CDCl3) 6 11.61 (1H, s), 10.38
(1H, s), 9.52 (1H, d, 1:81 HZ), 9.17 (1H, d, 1:60 HZ), 8.31
(1H, dd, 1:81, 6.0 HZ), 5.75 (1H, m), 5.03(1H, m), 4.81
(2H, m), 4.00 (1H, m), 3.37 (1H, m), 2.98 (3H, s), 18042.25
(4H, m), 1.64 (3H, s), 1.55 (3H, s), 1.39 (4H, m); 13C NMR
(75 MHZ, CDCl3) 6 147.49, 146.49, 144.86, 134.65, 132.20,
128.91, 123.74, 67.14, 62.95, 56.09, 38.69, 32.02, 31.67,
29.34, 27.87, 26.04, 21.91, 18.05; Anal. Calcd for
Cl9H32Br2N2.0.7H2O: C, 49.52; H, 7.28; N, 6.08. Found: C,
49.44; H, 7.18; N, 6.07.

methanol (1 mL). The solution Was diluted With ether (100
mL), Washed With Water, saturated aqueous NaHCO3 and
brine successively. The organic layer Was dried and concen
trated. The residue Was puri?ed by ?ash chromatography on
silica gel, eluting With hexane to afford 1-bromo-7-methyl
octane (1.28 g, 74%) as a colorless oil: 1H NMR (300 MHZ,

AcOH (10 ml) Was added 1-bromo-7-methyl-octane (1.20 g,

To a stired solution of (S)-nicotine (0.33 g, 2.0 mmol) in
AcOH (10 ml) Was added 8-bromo-2-methyl-oct-2-ene
(1.05 g, 5.12 mmol). The mixture Was heated at re?ux for 3
days. AcOH Was evaporated and the residue Was recrystal

liZed in ethyl acetate-CHCl3 to (S)-1-(7-methyl-oct-6-enyl)
3 -( 1 -methyl-pyrrolidin-2 -yl)-pyridinium bromide hydrobro

14b. 1-Bromo -7 -methyl-octane
To a solution of 7-methyl-octan-1-ol (1.20 g, 8.33 mmol)
in DMF (20 mL) Was added triphenylphosphine (2.43 g,

(S)-1-[2-(2-Ethoxy-ethoxy)-ethyl]-3-(1-methyl-pyr
rolidin-2 -yl) -pyridinium bromide (NONB -3060)
60

To a stirred solution of (S)-nicotine (0.67 g, 4.1 mmol) in
AcOH (20 ml) Was added 1-bromo-2-(2-ethoxy-ethoxy)

65

ethane (1.97 g, 10.0 mmol). The mixture Was heated at re?ux
for 3 days. AcOH Was evaporated and the residue Was
dissolved in CHCl3. The mixture Was Washed With saturated
aqueous NaHCO3, Water and brine successively and dried.

Evaporation of the solvent folloWed by titration With ether
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a?forded 0.56 g (38%) of (S)-1-[2-(2-ethoxy-ethoxy)-ethyl]

sulfate. Evaporation of the solvent a?‘orded 0.64 g (26%) of

3 -(1 -methyl-pyrrolidin-2 -yl)-pyridinium bromide (NONB

(S)-1-(12-acetoxy-dodecyl)-3 -(1-methyl-pyrrolidin-2-yl)

3060) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 6 9.65

pyridinium bromide (NADDNB) as a broWn oil. 1H NMR

(1H, d, 1:60 HZ), 9.26 (1H, s), 8.44 (1H, d, 1:78 HZ), 7.99
(1H, dd, 1:78, 6.0 HZ), 5.27 (2H, t, 1:48 HZ), 4.06 (2H, t,
1:48 HZ), 3.64 (2H, m), 3.414360 (5H, m), 3.26 (1H, m),
2.43 (2H, m), 2.25 (3H, s), 1.91 (2H, m), 1.60 (1H, m), 1.16
(3H, t, 1:69 HZ); 13C NMR (75 MHZ, CDCl3) 6 145.87,
144.40><2, 144.02, 127.85, 70.83, 69.72, 69.57, 67.17, 66.77,
61.41, 56.91, 40.67, 36.02, 23.41, 15.47; Anal. Calcd for
Cl6H27BrN2.0.5H2O: C, 52.18; H, 7.66; N, 7.61. Found: C,
52.22; H, 7.68; N, 7.50.

(300 MHZ, CDCl3) 6 9.58 (1H, d), 9.14 (1H, s), 8.46 (1H,
d), 8.08 (1H, t), 5.00 (2H, t), 4.04 (2H, t), 3.62 (1H, t), 3.29
(1H, t), 2.48 (2H, m), 2.28 (3H, s), 1.55*2.1(10, m),
14241.19 (17, m); 13C NMR (75 MHZ, CDCl3) 6 171.3,
144.2, 144.0, 143.0, 128.4><2, 67.2, 64.8, 62.4, 56.9, 40.7,
36.0, 32.3, 29.7><2, 29.6, 29.5, 29.4, 29.3, 28.8, 26.4, 26.1,

EXAMLE 16

[3H]-DA Release Assay

23.4, 21.3.
EXAMPLE 19

(S)-1-(9-Acetoxy-nonyl)-3 -(1-methyl-pyrrolidin-2

Rat striatal slices (500 um thickness, 648 mg Wet Weight)

yl) -pyridinium bromide (NANNB)

Were incubated for 30 minutes in Kreb’s bu?er (118 mM

To a stirred solution of (S)-nicotine (2.0 ml, 12.2 mmol)
in AcOH (25 ml) 1,9 dibromononane (1.28 g, 6.2 mmol) Was

NaCl, 4.7 mMKCl, 1.2 mM MgCl2, 1.0 mM NaH2PO4, 1.3
mM CaCl2, 11.1 mM glucose, 25 mM NaHCO3, 0.11 mM
L-ascorbic acid, and 0.004 mM disodium EDTA; pH 7.4,

20

added. The mixture Was re?uxed for 3 days. After evapo

and saturated With 95% O2/ 5% CO2) in a metabolic shaker

ration of the AcOH, the resulting residue Was basi?ed using
saturated aqueous NaHCO3. The resulting aqueous solution
Was extracted three times With ethyl ether folloWed by
extraction three times With chloroform. The chloroform
layers Were collected, dried over magnesium sulfate. Evapo
ration of the solvent a?forded 2.97 g (40%) of (S)-1-(9

at 340 C. Slices Were rinsed With 15 ml of fresh bu?er and
incubated for an additional 30 minutes in fresh bu?er

containing 0.1 uM [3]H-DA (6 slices/3 ml). Subsequently,
25

nomifensine (10 uM) and pargyline (10 uM) and maintained
at 340 C., pH 7.4, With continual aeration (95% O2/5% CO2).

acetoxy-nonyl) -3 -(1-methyl-pyrrolidin-2 -yl)-pyridinium
bromide (NANNB) as a broWn oil. 1H NMR (300 MHZ,

CDCl3) 6 9.60 (1H, d), 9.15 (1H, s), 8.47 (1H, d), 8.10 (1H,
t), 5.01 (2H, t), 4.04 (2H, t), 3.61 (1H, t), 3.29 (1H, t), 2.47

slices Were rinsed With 15 ml of fresh bu?er and transferred

to a glass superfusion chamber. Slices Were superfused (1.0
ml/min) for 60 minutes With Kreb’s bu?er containing

30

(2H, m), 2.28 (3H, s), 15442.10 (10, m), 13941.18 (17, m).

TWo ?ve minute samples (5 ml each) Were collected to
determine basal out?oW of [3H]-DA. Chain-modi?ed NONI
and NDNI analogs Were added to the superfusion bu?er after
the collection of the second sample and remained in the
bu?er until 12 consecutive ?ve minute samples Were col

EXAMLE 17
35

lected. Subsequently, S-(—)-nicotine (10 uM) Was added to

(S)-1-(11-Acetoxy-undecyl)-3 -(1-methyl-pyrrolidin

the bu?er and an additional 12 consecutive ?ve minute

2-yl)-pyridinium bromide (NAUNB)

samples Were collected. At the end of the experiment, each
slice Was solubiliZed and the [3H] content of the tissue
determined.

To a stirred solution of (S)-nicotine (2.0 ml, 12.5 mmol)
After evaporation of the AcOH, the resulting residue Was

Radioactivity in the superfusate and tissue samples Was
determined by liquid scintillation spectroscopy. Fractional
release for each sample Was calculated by dividing by the

basi?ed using saturated aqueous NaHCO3. The resulting

total tritium present in the tissue at the time of sample

in AcOH (25 ml) 1,11 dibromoundecane (1.47 ml, 6.2

40

mmol) Was added. The mixture Was re?uxed for 3 days.

aqueous solution Was extracted three times With ethyl ether
folloWed by extraction three times With chloroform. The
chloroform layers Were collected, dried over magnesium

45

sulfate. Evaporation of the solvent a?forded 2.80 g (36%) of

(S)-1-(11-acetoxy-undecyl)-3-(1-methyl-pyrrolidin-2-yl)

collection, and Was expressed as a percentage of total tissue
tritium. Basal [3H]out?oW Was calculated from the average
of the tritium collected in the tWo ?ve minute samples just
before addition of the chain-modi?ed NONI and NDNI
analog. The sum of the increase in collected tritium resulting
from either exposure to the test-compound or exposure to

pyridinium bromide (NAUNB) as a broWn oil. 1H NMR

(300 MHZ, CDCl3) 6 9.58 (1H, d), 9.13 (1H, s), 8.46 (1H,
d), 8.08 (1H, t), 4.99 (2H, t), 4.02 (2H, t), 3.62 (1H, t), 3.28
(1H, t), 2.48 (2H, m), 2.28 (3H, s), 15342.00 (10, m),
14141.17 (17, m).

50

EXAMPLE 18
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nicotine in the absence and presence of the test compound

equaled total [3H]over?oW. [3H]Over?oW Was calculated by
subtracting the [3H]out?oW during an equivalent period of
prestimulation from the values in samples collected during
and after drug exposure. Inasmuch as the radiolabelled

(S)-1-(12-Acetoxy-dodecyl)-3-(1-methyl-pyrrolidin

or [3 H]over?oW, rather than as [3H]-DA. [3H]Over?oW
primarily represents [3H] -DA in the presence of nomifensine
and pargyline in the superfusion bu?er.

2-yl)-pyridinium bromide (NADDNB)
To a stirred-solution of (S)-nicotine (0.603 ml, 3.75

60

mmol) in AcOH (25 ml) 1,12 dibromododecane (0.56 g,
1.71 mmol) Was added. The mixture Was re?uxed for 3 days.

After evaporation of the AcOH, the resulting residue Was

basi?ed using saturated aqueous NaHCO3. The resulting
aqueous solution Was extracted three times With ethyl ether
folloWed by extraction three times With chloroform. The
chloroform layers Were collected, dried over magnesium

compounds Were not separated and identi?ed, the tritium
collected in superfusate is referred to as either [3H]out?oW
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The chain-modi?ed NONI and NDNI analogs Were evalu
ated for their ability to evoke [3H] release from rat striatal
slices at three concentrations (0.1, 1 and 10 uM). In addition,
the classical competitive nicotinic antagonist DHBE Was
also examined in this assay for comparison. None of the
compounds examined at concentrations beloW 10 uM had

any signi?cant [3H]-DA releasing properties in this assay.
Since striatal NIC-evoked [3H]-DA release is thought to be

US 7,091,357 B2
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mediated through a mechanism involving the putative
0662* receptor subtype, these compounds do not possess

nM [3H]-NIC (50 pl) and one of at least nine concentrations
of chain-modi?ed NONI and NDNI analog (50 pl). After a

signi?cant agonist activity at this subtype.

90 min incubation at 4° C., reactions Were terminated by
dilution of the samples With 3 ml of ice-cold Krebs-HEPES

The chain-modi?ed NONI and NDNI analogs Were also

buffer folloWed immediately by ?ltration through Whatman
GF/B glass ?ber ?lters (presoaked in 0.5% polyethylene

evaluated for their ability to inhibit NIC evoked [3H]-DA
release. In these experiments, striatal slices Were superfused
for 60 minutes With various concentrations of the analogs

imine) using a Brandel Cell Harvester. Filters Were rinsed
three times With 3 ml of ice-cold Krebs-HEPES buffer,
transferred to scintillation vials, and 5 ml scintillation cock

prior to NIC (10 pM) exposure. Antagonist activity Was
evaluated by comparing the NIC-evoked [3H]over?oW in the
absence and presence of the analogs. The relative order of
potency of these chain-modi?ed NONI and NDNI analogs
for inhibition of NIC-evoked [3H]-DA release from rat
striatal slices is provided in Table 1 by a comparison of their

tail (Research Products International Corp., Mt. Prospect,
Ill.) added. Nonspeci?c binding determined in triplicate Was

IC5O values.

squares nonlinear regression analysis.

de?ned as binding in the presence of 10 pM NIC. Binding
parameters Were determined using the Weighted, least
The chain-modi?ed NONI and NDNI analogs Were evalu

TABLE 1

ated for their ability to displace [3H]-NIC binding from rat

IC5Os for Chain-modi?ed NONI and NDNI Analogs in

Furthermore, the displacement by the analogs Was compared

striatal membranes. The results are summariZed in Table 2.
the S—(—)—NIC-evoked PHI-DA Release Assay

Compound

IC5O (pM)

NONI
NDNI

0.62
>100

DHBE

3 .60

NONB-3t
NDNB-4t
NONB-3c
NDNB-4c
NONB-7e

3 .47
0.33
2.02
1 .48
2.61

to that produced by DHBE (Ki:150 nM).
20

TABLE 2
Speci?c Binding of [3H]—NIC to Rat Striatal Nicotinic
Acetylcholine Receptors in the Presence of chain
modi?ed NONI and NDNI analogs
25

NUNB- 10e

NCyNB-4
NCyNB-5
NCyNB-6

30

NONB-3y
NDNB-3y

1.68
2.59

NONB-6e7M
NONB-7M
NONB-306O
NANNB
NADNI
NADDNB

Compound

K; (pM)“

NONI
NDNI

20
0.093

DHBE

0.15

NONB-3t
NDNB-4t
NONB-3c
NDNB-4c
NONB-7e

3.97
0.32
0.086
7.79
0.45

NCyNB-4
NCyNB-5
NCyNB-6
NONB-3y
NDNB-3y

7.20
5.54
4.56
0.20
0.81

NONB-6e7M
NONB-7M
NONB-306O
NANNB
NADNI
NADDNB

0.45
0.44
1.20

1.99
>100
35
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EXAMPLE 20

[3H]-NIC Binding Assay
Striata from tWo rats Were dissected, pooled, and homog
eniZed With a Tekmar polytron in 10 volumes of ice-cold

modi?ed Krebs-HEPES buffer (20 mM HEPES, 118 mM
NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4,
adjusted to pH 7.5). The homogenates Were incubated at 37°
C. for 5 minutes and centrifuged at 15,000 g for 20 minutes.
The pellet Was resuspended in 10 volumes of ice-cold
MilliQ Water, incubated for 5 minutes at 37° C., and cen
trifuged at 15,000 g for 20 mm. The second pellet Was then
resuspended in 10 volumes of fresh ice-cold 10% Krebs
HEPES buffer, incubated at 37° C., and centrifuged at
15,000 g for 20 minutes. The latter sequence of resuspen

45 3Data are expressed as fmol/mg of protein of at least 3 independent

experiments. Speci?c binding is calculated as the difference between the
total binding of3 nM [3H]—NIC to the receptors alone and nonspeci?c
binding in the presence of 10 pM nicotine.
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[3 H] -MLA Binding Assay
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sion, incubation, and rentrifugation Was repeated. The pellet
Was froZen under fresh 10% Krebs-HEPES buffer and stored
at —40° C. until assayed. Upon assay, the pellet Was resus

pended in the Krebs-HEPES buffer, incubated at 37° C. for
5 minutes, and centrifuged at 15,000 g for 20 mm. The ?nal
pellet Was resuspended in 3.6 ml ice-cold MilliQ Water

60

Which provided for approximately 200 pg protein per 100 pl
aliquot. Competition assays Were performed in triplicate in
a ?nal volume of 200 pl Krebs-HEPES buffer containing
250 mmol Tris buffer (pH 7.5 at 4° C.). Reactions Were
initiated by addition of 100 pl of membrane suspension to 3

EXAMPLE 21

Rat brain tissue (Without cortex, striatum and cerebellum)
Was homogeniZed With a Tekmar Polytron (setting 40) in 20
volumes of ice-cold hypotonic buffer (2 mM HEPES, 14.4
mM NaCl, 0.15 mM KCl, 0.2 mM CaCl2 and 0.1 mM
MgSO4, pH:7.5). The homogenate Was incubated at 37° C.
for 10 minutes and centrifuged at 25,000><g for 15 minutes
at 40° C. The pellet Was Washed 3 times more by resuspen
sion in the 20 volumes of the same buffer and centrifugation
at the above parameters. The ?nal pellet Was stored at —20°
C. under 4.6 ml of the incubation buffer and Was suspended

just before the incubation With radioligand.
65

The binding of [3H]methyllycaconitine ([3H]MLA), a
probe for the (x7 neuronal nicotinic acetylcholine receptor
subtype, Was determined using a modi?cation of the method

US 7,091,357 B2
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R1 is selected from the group consisting of hydrogen,
loWer straight chain or branched alkyl, cycloalkyl,

of Davies et al., “Characterisation of the binding of [3H]
methyllycaconitine: a neW radioligand for labelling (x7-type

substituted cycloalkyl, aryl and aralkyl;

neuronal nicotinic acetylcholine receptors”, Neuropharma
cology, 38, 6794690 (1999). [3H]-MLA (25.4 Ci/mmol) Was
purchased from Tocris Cookson Ltd., Bristol, UK. Binding

R2, Z1 and Z4 are each independently selected from the
group consisting of hydrogen, loWer alkyl, loWer
branched alkyl, loWer alkenyl, and loWer branched

Was performed in duplicate, in a ?nal volume of 250 ML of

alkenyl;

the incubation medium, containing 20 mM HEPES, 144 mM
NaCl, 1.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4 and 0.05%
BSA, pH:7.5. Reaction Was initiated by the addition of 100
pl of membrane suspension to the samples containing a
desired concentration of test compounds and 2.5 nM [3H]

A and B are carbon;

R3, R4, Z2 and Z3 are each independently selected from
the group consisting of hydrogen; alkyl; substituted

alkyl; cycloalkyl; substituted cycloalkyl; substituted
alkenyl; substituted alkenyl; alkynyl; substituted alky
nyl; aryl; substituted aryl; alkylaryl; substituted alky
laryl; arylalkyl; substituted arylalkyl; arylalkenyl; sub
stituted
arylalkenyl;
arylalkynyl;
substituted

MLA (?nal concentration) and incubated for 2 hours at room
temperature. Total binding Was measured in the absence of

unlabelled ligand, and nonspeci?c binding Was determined
in the presence of 1 uM unlabelled MLA. The binding
reaction Was terminated by dilution of samples With 3 ml of
ice-cold incubation buffer folloWed by immediate ?ltration

arylalkynyl;
R5 is selected from the group consisting of alkyl; substi

through presoaked in 0.5% polyethylenimine glass ?ber
?lters (S&S, grade #32) using a Brandel harvester system.
Filters Were rinsed three times With 3 ml of ice-cold buffer,
transferred to scintillation vials and 4 ml of scintillation
cocktail Was added. Protein Was measured using the Brad
ford dye-binding procedure With bovine serum albumin as
the standard.
In order to determine if these compounds have affinity at

20

arylalkynyl, With the proviso that R5 of R optical
25

the (X7 receptor subtype, the chain-modi?ed NONI and
NDNI analogs Were evaluated for their ability to displace
[3H] -MLA binding from rat brain membranes, as a re?ection
of their interaction With the (X7 receptor (Table 3). In

addition, the classical (X7 receptor antagonist ot-bungaro

and B are carbon;

30

3. The compound according to claim 1, Wherein said
35

compound is (S)-trans-1-dec-4-enyl-3-(1-methyl-pyrrolidin
2-yl)-pyridinium bromide.
4. The compound according to claim 1, Wherein said

compound is (S)-cis-3-(1-methyl-pyrrolidin-2-yl)-1-oct-3
enyl-pyridinium bromide hydrobromide salt.

The purpose of the above description and examples is to

be made to the composition and method of the present
invention Without departing from the spirit or scope of the
invention. All patents and publications cited herein are

2HSO4, S02, 2CH3SO3, 2p-TsO and 2CF3SO3.
2. The compound according to claim 1, Wherein said

compound is (S)-trans-3-(1-methyl-pyrrolidin-2-yl)-1-oct
3-enyl-pyridinium bromide hydrobromide salt.

concentration>100 11M.
illustrate some embodiments of the present invention With
out implying any limitation. It Will be apparent to those of
skill in the art that various modi?cations and variations may

isomer of Formula (VI) is not iCH2OH When A and
B are carbon, and R5 of the S optical isomer of Formula
(VI) is not hydrogen, 4CH2NH2 or 4CH2Ph When A

R6 is hydrogen; and
Y is selected from the group consisting of 2C1, 2Br, 2I,

toxin Was also examined in this assay for comparison.

ot-Bungarotoxin afforded a K,- value of 7.2 nM in the above
assay. The results from the competition binding assay
shoWed that NCyNB-4, NCyNB-5, and NCyNB-6 had Ki’s
of 30.3 11M, 88.7 11M, and 42.7 11M, respectively. None of the
other chain-modi?ed NONI and NDNI analogs possessed
any signi?cant binding af?nity in the [3H]-MLA assay at

tuted alkyl; cycloalkyl; substituted cycloalkyl; alkenyl;
substituted alkenyl; alkynyl; substituted alkynyl; aryl;
substituted aryl; arylalkyl; substituted arylalkyl; aryla
lkenyl; substituted arylalkenyl; arylalkynyl; substituted
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5. The compound according to claim 1, Wherein said

compound is (S)-cis-1-dec-4-enyl-3-(1-methyl-pyrrolidin-2
yl)-pyridinium bromide hydrobromide salt.
6. The compound according to claim 1, Wherein said

45

incorporated by reference in their entireties.

compound is (S)-1-dec-9-enyl-3-(1-methyl-pyrrolidin-2-yl)
pyridinium bromide.
7. The compound according to claim 1, Wherein said

compound is (S)-1-(6-cyclobutyl-hexyl)-3-(1-methyl-pyrro
lidin-2-yl)-pyridinium bromide hydrobromide salt.

What is claimed is:

1. A compound including resolved enantiomers and dias
tereoisomers thereof selected from a formula consisting of

formula (VI):

8. The compound according to claim 1, Wherein said
50

compound is (S)-1-(6-cyclopentyl-hexyl)-3-(1-methyl-pyr
rolidin-2-yl)-pyridinium bromide hydrobromide salt.
9. The compound according to claim 1, Wherein said

compound is (S)-1-(6-cyclohexyl-hexyl)-3-(1-methyl-pyr
rolidin-2-yl)-pyridinium bromide hydrobromide salt.

(V1)
55

10. The compound according to claim 1, Wherein said

compound is (S)-1-(7-methyl-oct-6-enyl)-3-(1-methyl-pyr
rolidin-2-yl)-pyridinium bromide hydrobromide.
11. The compound according to claim 1, Wherein said
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compound is (S)-1-(7-methyl-octyl)-3-(1-methyl-pyrroli
din-2-yl)-pyridinium bromide hydrobromide salt.
12. The compound according to claim 1, wherein R1 is
hydrogen or straight chain or branched alkyl having 1410
carbons, R5 is a branched or non-branched C(Cl9 alkyl

having 4419 carbons, cycloalkyl, alkenyl, alkynyl, aryl,
65

Wherein

Q is methylene;

arylalkyl, arylalkenyl or arylalkynyl; and Y is 2Br or 21.

13. The compound according to claim 1, wherein R1 is

methyl, ethyl, isopropyl or isobutyl; R2 is hydrogen; and R3

US 7,091,357 B2
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and R4 are individually hydrogen, halogen, alkyl or alkyol,
R5 is a branched or non-branched C4£19 alkyl having 4*19

non-branched C4£19 alkyl having 4*19 carbons,
cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl or

carbons, cycloalkyl, alkenyl, alkynyl, aryl, arylalkyl, aryla

arylalkynyl; Z1, Z2, Z3 and Z4 are hydrogen; andY is 2Br or

lkenyl or arylalkynyl; Z1, Z2, Z3 and Z4 hydrogen; Y is 2Br

21.

or 21.

14. The compound according to claim 1, wherein R1 is
methyl; R2 is hydrogen; and R3 and R4 are individually
hydrogen, halogen, alkyl or alkyol, R5 is a branched or

15. The compound according to claim 1, Wherein said

compound is substantially optically pure.
*

*

*

*
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